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Influenza A virus (IAV) increases morbidity and mortality rates and novel antivirals are 
needed to combat the virus. Errors of the viral polymerase lead to the generation of 
defective RNAs. These DI-RNAs may interfere with wild-type (wt) IAV infection and may be 
packaged into defective interfering particles (DIPs), which exhibit antiviral activity. DIPs 
inhibit IAV infection by competing with wt IAV for cellular and viral resources required for 
genome replication (replication interference) and by inducing interferon (IFN). DI-244 is a 
prototypic DI-RNA derived from IAV genomic segment 1 that harbours a large central 
deletion, it exerts potent antiviral activity and is considered for the development as antiviral. 
However, it is unclear whether DI-244 inhibits IAV via replication interference and/or IFN 
induction. Moreover, there is no system available to produce DI-244 in the absence of wt 
IAV, which raises safety concerns. The goal of this thesis was to close these research gaps by 
engineering MDCK cells to express codon optimized PB2 (PB2opt). 
The PB2 open reading frame is destroyed in DI-244 and this defect should be complemented 
by the PB2 provided in trans. Indeed, MDCK-PB2opt cells in absence of wt IAV were able to 
produce DI-244 merely from plasmids. The generated DI-244 exerted strong antiviral activity 
against H1N1 and H3N2 IAV, but not against a dissimilar virus (vesicular stomatitis virus 
(VSV)). Furthermore, MDCK-PB2opt cells were successfully used to quantify DI-244 infectivity 
and thus constituted a useful tool to study how DI-244 inhibits IAV infection. This research 
revealed that any deletion in IAV genomic segment 1 could convert it into a DI-RNA and the 
antiviral activity was inversely correlated with DI-RNA length in the absence of a functional 
IFN system. In the presence of a functional IFN system, DI-244 induced a robust, partially 
STAT1-independent anti-IAV activity that was not determined by DI-RNA length and was 
more potent than DIP-mediated replication interference. Interestingly, RNAseq analysis and 
quantitative RT-PCR revealed that DI-244 induced expression of IFN-stimulating genes (ISGs) 
but not IFN, suggesting that DIPs might stimulate ISG expression via a novel pathway. In 
summary, the present study reports a system that allows production of DIPs in the absence 
of wt IAV and provides evidence that induction of the IFN system is a major contributor to 
DIP antiviral activity. Though, the induction of the IFN system does not involve DIP-






Die Infektion mit dem Influenza-A-Virus (IAV) ist für hohe Morbidität und Mortalität 
verantwortlich und neue antivirale Medikamente werden dringend benötigt. Fehler der 
viralen Polymerase führen zur Bildung von defekten RNAs. Diese RNAs können mit der wt 
IAV-Infektion interferieren und in defective interfering particles (DIPs) verpackt werden, die 
antivirale Aktivität aufweisen. DIPs hemmen die IAV-Infektion indem sie mit wt IAV um 
Ressourcen konkurrieren, die für die Genomreplikation benötigt werden 
(Replikationsinterferenz), und indem sie das Interferon (IFN)-System aktivieren. DI-244 ist 
eine prototypische DI-RNA, die sich von dem genomischen Segment 1 von IAV ableitet und 
eine zentrale Deletion aufweist. DI-244 wirkt stark antiviral und könnte die Basis für ein 
neues Medikament darstellen. Es ist jedoch unklar, ob DI-244 die IAV-Infektion durch 
Replikationsinterferenz und/oder IFN-Induktion hemmt. Darüber kann DI-244 nicht ohne wt 
IAV hergestellt werden, was Sicherheitsbedenken aufwirft. Das Ziel dieser Arbeit war es, 
diese Forschungslücken zu schließen. 
Für die Produktion von DI-244 ohne IAV wurden MDCK-Zellen hergestellt, die 
kodonoptimiertes PB2 (PB2opt) exprimieren. Das PB2-Leseraster in DI-244 ist zerstört und 
dieser Defekt sollte durch das in trans bereitgestellte PB2 komplementiert werden. 
Tatsächlich gelang es DI-244 in MDCK-PB2opt Zellen mit Hilfe von Plasmiden und ohne wt 
IAV herzustellen. Das so erzeugte DI-244 hemmte H1N1- und H3N2-IAV und die DIP- 
Infektiosität konnte mit Hilfe der MDCK-PB2opt-Zellen quantifiziert werden. Mechanistische 
Analysen zeigten, dass jede Deletion im IAV-Genomsegment 1 dieses in eine DI-RNA 
verwandelte, deren antivirale Aktivität in Abwesenheit eines funktionierenden IFN-Systems 
invers mit der Länge der DI-RNA korrelierte. In IFN-kompetenten Zellen induzierte DI-244 
eine robuste, teilweise STAT1-unabhängige anti-IAV-Aktivität, die nicht durch die DI-RNA-
Länge bestimmt wurde und die stärker war als die DIP-vermittelte Replikationsinterferenz. 
Interessanterweise zeigten RNAseq- und PCR-Analysen, dass DI-244 die Expression von IFN-
stimulierten Genen (ISGs), aber nicht von IFN induzierte, was darauf hindeutet, dass DIPs die 
ISG-Expression über einen neuartigen Weg stimulieren können. Zusammenfassend zeigt 
diese Arbeit, dass DIPs in Abwesenheit von wt IAV hergestellt werden können und IFN-
unabhängig die ISG-Expression induzieren, was wahrscheinlich wesentlich zu ihrer 





3 Introduction  
3.1 Viruses 
Viruses are intracellular parasites which require host cells for their replication. They harbour 
genetic material (DNA or RNA) that is protected by a protein shell and, for some viruses, a 
membrane. Viruses enter host cells by binding to surface receptors and hijack the 
biosynthesis machinery of the cell for gene expression and genome replication. Mutations 
occurring during genome replication can provide viruses with new biological properties, for 
instance, the ability to infect new hosts or to evade the immune response. Infection with 
well-studied viruses like human immunodeficiency virus (HIV) and influenza viruses is 
responsible for considerable global morbidity and mortality. Moreover, the emergence of 
new, highly transmissible viruses can threaten human health and economies, as evidenced 
by the current COVID-19 pandemic, which is caused by a novel coronavirus, the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). 
3.1.1 Influenza Viruses 
Influenza viruses cause acute infections of the respiratory tract. Symptoms usually last up to 
3-7 days and include sore throat, cough, fever, running nose, chills, and muscle aches (Ohmit 
and Monto 2006; Monto et al. 2000; Public Health England 2019). Influenza virus infection 
can also cause severe illness or death, especially in people with comorbidities, pregnant 
women, individuals with compromised immune system (Ramsay 2019) and infants aged 6 
months or younger (Cromer et al. 2014). Influenza viruses spread via droplets released by an 
infected person through sneezing and coughing, but also by contact with contaminated 
surfaces (Lau et al. 2010). The World Health Organisation (WHO) estimates that 3-5 million 
cases of severe illness and 0.3-0.5 million deaths occur annually worldwide due to recurring 
seasonal influenza (WHO 2020b). Furthermore, influenza pandemics may result in millions of 
deaths as seen with the so-called Spanish influenza in 1918. 
Influenza viruses belong to the family Orthomyxoviridae and are enveloped viruses with a 
segmented, negative-stranded RNA genome (Shaw and Palese 2013). They are divided into 4 
different genera: influenza A, B, C and D viruses (WHO 2020a, 2020c; Ghebrehewet et al. 
2016). Influenza A viruses (IAV) are further classified into subtypes according to their 
hemagglutinin (HA) and neuraminidase (NA) proteins and at present 18 different subtypes of 





and H18) and NA (N10 and N11) subtypes have recently been identified in bats (Tong et al. 
2012; Tong et al. 2013). Influenza B viruses (IBV) are classified into 2 lineages – Victoria and 
Yamagata (Bennett et al. 2015; WHO 2020a, 2020c). Influenza virus strains are named 
according to their genus (type), the species from which the virus was isolated, the 
geographical location where the isolate was obtained, the number of the isolate, and the 
year of isolation (Shaw and Palese 2013). For example, A/Puerto Rico/8/34 (H1N1) 
designates 8th isolate of an IAV strain that was isolated from a human patient in Puerto Rico 
in 1934 and has antigenic subtypes 1 for both HA and NA (Krug 1989). A/Puerto Rico/8/34 
hereafter will be referred to as PR8. Influenza A, B and C viruses are known to infect humans 
(Webster et al. 1992) while influenza D viruses mainly infect pigs and cattle (Hause et al. 
2014; Ferguson et al. 2015). Both IAV and IBV can induce severe influenza but only IAV 
causes both epidemics and pandemics. Influenza C viruses cause only mild illness (Matsuzaki 
et al. 2016) and are clinically not relevant. 
Influenza viruses are spherical or filamentous in form with an average diameter of 100 nm  
and a length of 300 nm (Bouvier and Palese 2008). Particles contain an envelope, the viral 
genome, and viral proteins. A schematic diagram of the IAV structure is depicted in Figure 
3.1. Its envelope is formed by a lipid bilayer that harbours three viral proteins, HA, NA and 
the ion channel (M2). A layer of matrix protein (M1) is located below the membrane and the 
particle interior contains eight segments of genomic viral RNA (vRNA) associated with viral 
proteins in a ribonucleoprotein (vRNP) complex (Bouvier and Palese 2008). 
Each of the eight vRNP contains vRNA associated with nucleoprotein (NP) and the viral RNA-
dependent RNA polymerase (RdRp), which consists of the subunits polymerase basic 1 (PB1) 
and 2 (PB2) and polymerase acidic (PA) (Nogales and Martínez-Sobrido 2016). The coding 
region of each vRNA is flanked by non-coding regions (NCR) which are conserved for each 
segment among all IAV strains. The NCRs act as promoters to initiate RNA replication and 
mRNA expression. Sequences adjacent to the NCRs are segment-specific and together with 
the NCRs form the packaging signals required for the incorporation of vRNPs into progeny 
viral particles as well as polyadenylation signals. The eight segments vary in length with the 
segment encoding PB2 being the longest and the segment encoding the non-structural (NS) 
proteins being the shortest. Each viral segment encodes one or more viral proteins with 






Figure 3.1 A schematic diagram of influenza A virus particle structure. The HA, NA, and matrix (M2) proteins 
are inserted into the lipid bilayer. Matrix protein (M1) surrounds the nucleocapsid, which compromises eight 
ssRNA segments associated with nucleoprotein (NP). The eight RNA segments encode 10 proteins: 3 
polymerase subunits (PB2, PB1, PA), HA, NP, NA, M1, M2, NS1, and NEP. Black lines in the vRNA segments 
represent ’ and ’ non-coding regions (NCR). PB1 and PB2, polymerase basic 1 and 2; PA, polymerase acidic; 
NP, nucleoprotein; M, Matrix; NS, non-structural; NEP, nuclear export protein. [Taken from (Nogales and 
Martínez-Sobrido 2016)] 
Table 3.1 Length and function of genome segments of influenza A virus (Bouvier and Palese 2008) *(Hayashi et 













(Open reading frame 
overlapping with 
PB1) 







Polymerase acidic Endonuclease activity, protease 
Host shut-off* 
4 1778 HA Hemagglutinin Major antigen, receptor binding, 
membrane fusion  
5 1565 NP Nucleoprotein RNA binding, RNP nuclear export  
6 1413 NA Neuraminidase Sialidase activity, virus release 
7 1027 M1 Matrix protein 1 vRNP and glycoprotein interaction, 
RNP nuclear export, assembly and 
budding  
M2 Matrix protein 2 Ion channel activity, virus uncoating 
and assembly  
8 890 NS1 Non-structural 
protein 1 




protein 2/ Nuclear 
Export protein 





3.1.1.1 Biology of influenza A viruses  
Influenza A viruses (IAVs) infect diverse mammals, including humans, pigs, dogs, cats, and 
birds (Webster et al. 1992; Hussain et al. 2017). The natural reservoir host of IAVs are wild 
aquatic birds (Webster et al. 1992). The interspecies transmission of IAVs and the constant 
adaptation of these viruses to immune pressure promotes antigenic variation in HA and NA 
(Neumann et al. 2009). Thus, the constant acquisition of point mutations in NA and 
particularly in HA during the circulation of IAV and IBV in humans allow these viruses to 
evade antibody-mediated neutralization and to continuously spread in immunologically non-
naïve human populations. This process is termed antigenic drift (Paules and Subbarao 2017) 
and the mutations arise due to the absence of a proof-reading activity of the viral RNA-
dependant RNA polymerase (RdRp) (Cox and Subbarao 2000; Bennett et al. 2015). Antigenic 
drift is responsible for seasonal epidemics and for the constant need to reformulate vaccines 
(Paules and Subbarao 2017). Novel IAV can arise when two or more IAV coinfect cells and 
exchange genomic segments, which is termed reassortment. If these IAV harbour 
antigenically novel HA and NA proteins, i.e. proteins against which humans have not pre-
existing immunity, this process is called antigenic shift.  It may result in IAVs that can rapidly 
spread in the human population and lead to influenza pandemics (Paules and Subbarao 
2017; Ramsay 2019) . 
The deadliest known pandemic was the so-called Spanish influenza (Spanish flu) which 
occurred in 1918. The responsible H1N1 virus was the result of a reassortment of a human 
H1 and an avian N1 subtype virus and caused over 50 million deaths worldwide (Frost 1919; 
Neumann et al. 2009; CDC 2019a). The next IAV pandemic occurred in 1957 and is termed 
Asian flu. It was caused by an H2N2 virus, which emerged due to reassortment of the then 
circulating seasonal H1N1 IAV with an avian IAV, and resulted in 1-2 million deaths 
(Neumann et al. 2009; CDC 2019b). The next influenza pandemic was recorded in 1968 and 
is termed Hong Kong flu. It was caused by an H3N2 virus that emerged due to reassortment 
between the then circulating seasonal virus of the H2N2 subtype and an avian H3 subtype 
(Neumann et al. 2009). About 1 million deaths are attributed to the Hong Kong flu (CDC 
2019c). The most recent influenza pandemic was the 2009 Swine flu. The responsible virus 
originated from reassortments between human H3N2, North American avian and H1N1 





virus (Dawood et al. 2009; Neumann et al. 2009). The total number of deaths attributed to 
swine flu was 150,000-575,000 (CDC 2019d) and the consequences of the swine flu were 
thus comparable to that of seasonal influenza. 
In the past decades, IAV subtypes such as H5N1, H7N9, and H10N8 originating from birds 
were transmitted to humans, but human infection frequently requires close contact and 
exposure to high amounts of virus, which limits the transmissibility of these viruses (Lu et al. 
2016). 
3.1.1.2 Replication Cycle 
The replication cycle of IAV begins with the binding of the viral HA to cell surface proteins 
and lipids modified with sialic acids (Dou et al. 2018), where the HA of human and avian IAV 
subtype attaches to α-2,6-linkages and α-2,3-linkages, respectively (Bouvier and Palese 
2008). Following attachment, the virus is taken up into endosomal compartment, where the 
low pH environment stimulates the next steps required for infection. First, it initiates a 
conformational change in HA and that results in fusion between the viral and the endosomal 
membrane (Dou et al. 2018). Membrane fusion requires cleavage of HA by the cellular serine 
protease TMPRSS2 (transmembrane protease serine S1 member 2) in infected cells 
(Böttcher et al. 2006) or addition of trypsin to the culture medium (Klenk et al. 1975). The 
only exception is A/Wilson-Smith Neurotropic/33 (A/WSN/33) for which NA ensures HA 
cleavage by recruiting plasminogen (Goto and Kawaoka 1998; Goto et al. 2001; Chaipan et 
al. 2009). A/WSN/33 hereafter will be referred to as WSN. 
Second, the hydrogen ions are transported via the M2 ion channel into the interior of virus 
particles, which facilitates disassembly by abrogating protein-protein interactions (Shaw and 
Palese 2013). This allows release of viral ribo-nucleoprotein (vRNPs) particles into the 
cytoplasm and subsequent transport to the nucleus (Dou et al. 2018). In the nucleus, the 
viral polymerase, consisting of PB1, PB2 and PA transcribes the vRNA into ’ capped and ’ 
polyadenylated mRNAs. For this, the viral polymerase cuts cellular mRNAs near the ’ end 
and uses the resulting small RNA segments as primers for transcription, a process termed 
cap snatching. Viral mRNA is then exported to the cytoplasm for translation of viral proteins 
(HA, NA and M2). Moreover, the viral polymerase generates complementary RNA (cRNA), 





transported into cytoplasm by M1 and NS2/NEP where assembly of progeny virions occurs 
thereafter released by budding from the plasma membrane (Te Velthuis and Fodor 2016). 
 
Figure 3.2 Influenza A virus replication cycle. The virus is engulfed after binding to cell surface receptors 
followed by endocytosis. After fusion of endosomal and viral membrane vRNPs are released into the 
cytoplasm. Subsequently, they are imported to the nucleus for viral replication and transcription. Thereafter, 
viral mRNA is exported for the translation of viral proteins to the cytoplasm. Finally, virus assembles and buds 
from the cell surface (Te Velthuis and Fodor 2016). 
3.1.1.3 Reverse genetics system of influenza A virus 
The generation and modification of recombinant influenza viruses require reverse genetics 
systems. The first reverse genetics system was established in 1999 using twelve plasmids: 
four expression plasmids for the viral RdRp complex and NP for reconstitution of vRNP and 
eight RNA polymerase-I (Pol-I) driven plasmids for transcription of vRNA segments 
(Neumann et al. 1999). Later the use of bidirectional plasmids allowed complete 
reconstitution of influenza virus from only 8 plasmids (Hoffmann et al. 2000a; Hoffmann et 
al. 2000b; Hoffmann 2002) (Figure 3.3 A). The highlight of this system is that each plasmid 
contains RNA Pol-I and-II promoters in opposite directions which, using the same cDNA, 
drive the expression of vRNA and encoded protein(s), respectively (Figure 3.3 A). Briefly, 
human Pol-I promoter and mouse Pol-I terminator are used to synthesize influenza vRNAs. 
Pol-I transcribes vRNA which is recognised by the viral polymerase complex. A Pol-II 
dependent cytomegalovirus promoter and a polyadenylation sequence direct the synthesis 





recombinant influenza viruses harbouring reporter genes were constructed and used to 
study virus replication and spread within the cell culture and in mice (Manicassamy et al. 
2010; Eckert et al. 2014; Nogales et al. 2015; Breen et al. 2016). 
The generation of recombinant influenza virus involves transfection of eight bi-directional 
plasmids into a co-culture of 293T and Madin-Darby Canine Kidney (MDCK) cells, where 293T 
cells provide high transfection efficiency while MDCK cells are known to provide high 
infectious titers (Martínez-Sobrido and García-Sastre 2010). During transfection of cells with 
these plasmids, PoI-I generates the eight-negative sense vRNAs while Pol-II directs the 
synthesis of viral proteins which are translated from viral mRNAs. Following translation, NP 
and polymerase complex associate with vRNAs to form vRNP complex (Figure 3.3 B) (Nogales 




Figure 3.3 Influenza vRNA cloning and reverse genetics A) vRNA cloning into ambisense plasmid: a bi-
directional vector containing hPol-I and T1 to direct the synthesis of the vRNAs. In opposite orientation to Pol-I 
cassette, a Pol-II and aBGH directs the synthesis of proteins from same viral cDNAs hPol-I, human polymerase-I 
promoter; T1, mouse pol-I terminator; Pol-II, polymerase-II cytomegalovirus promoter; aBGH, polyadenylation 
signal of the gene encoding bovine growth hormone; Ori, plasmid origin of replication; Ampr, Ampicillin 
resistance gene B) In cells transfected with ambisense plasmids, the Pol-I cassette generates 8 (-) vRNAs while 
the Pol-II directs the synthesis of 8 viral mRNAs that are translated into viral proteins.(Nogales and Martínez-
Sobrido 2016) 
3.2 Prophylaxis and Therapy 
Infants, immunocompromised patients and the elderly are at risk of developing severe or 





most effective protection (Houser and Subbarao 2015). However, vaccines against seasonal 
influenza will offer little to no protection against pandemic influenza. Besides vaccines, anti-
influenza drugs targeting viral proteins are available to combat influenza. Though, they have 
certain shortcomings such as high resistance, no activity against IBV and associated with side 
effects (Li et al. 2018).  
3.2.1 Vaccines 
Anti-IAV vaccines need to be reformulated on an annual basis due to antigenic drift. The 
current seasonal influenza vaccines are trivalent (H1N1, H3N2, one strain of IBV) or 
quadrivalent (H1N1, H3N2, two strains of IBV) (WHO 2020c; Grohskopf et al. 2019). Three 
classes of licenced vaccines are available. Inactivated influenza vaccines (IIV) contain non-
infectious particles and are commonly used. Live attenuated influenza vaccine (LAIV) 
contains a mixture of four strains of infectious influenza viruses with temperature-sensitive 
and attenuating mutations (Coelingh et al. 2014). Recombinant influenza vaccine (RIV) uses 
the baculovirus expression system or other viral vectors for production of recombinant HA 
(Grohskopf et al. 2019) 
Influenza vaccines are frequently generated in embryonated chicken eggs. The production 
involves isolation of selected strains, virus propagation in the allantoic cavity of eggs, 
harvesting, inactivation, purification and concentration (Stöhr et al. 2012). Despite being a 
well-established process, the whole vaccine production is time-consuming with several 
drawbacks such as limited availability of eggs, allergic reactions to residual egg protein and 
adaptation of influenza viruses to spread in eggs (Houser and Subbarao 2015). In the past 
decade, cell-based influenza vaccines were developed and are available for human 
treatment (Gallo-Ramírez et al. 2015). They are produced in three different cell lines: MDCK 
cells, African monkey kidney epithelial cells (Vero) or primary cultures of human retinoblasts 
(PER.C6) (Milián and Kamen 2015). The use of cell-based vaccines avoids allergic reactions to 
individuals sensitive to egg proteins, lowers the risk of contamination of eggs as a substrate, 
and provides easier and less expensive purification of the desired antigen and high scalability 
(Rappuoli 2006; Hegde 2015). However, despite the advancement in cell-culture vaccines, 





3.2.2 Anti-influenza drugs 
Different classes of antiviral drugs have been approved for influenza treatment and the 
drugs target different steps of the viral replication cycle.  
The first class of antivirals approved are the adamantanes (Hayden et al. 1980), amantadine 
and rimantadine, which block the M2 ion channel and thereby inhibit viral disassembly (Hay 
et al. 1985). However, viruses rapidly acquire mutations in M2 that causes drug resistance 
(Hussain et al. 2017; Han et al. 2018). Therefore, use of M2 inhibitors is not recommended. 
The second class are NA inhibitors: oseltamivir, zanamivir, peramivir and laninamivir inhibit 
NA activity and prevent viral spread (Hussain et al. 2017; Han et al. 2018). Nevertheless, 
viruses can acquire resistance conferring mutations, particularly against oseltamivir. For 
example, a mutation occurred in the NA of 2009 pandemic H1N1 virus strain, resulting in the 
inactivity of the oseltamivir drug (Morlighem et al. 2011). 
The third class of inhibitors is represented by Arbidol, which inhibits HA-driven membrane 
fusion. This drug is licenced in Russia and China for treatment of seasonal influenza (Paules 
and Subbarao 2017). 
The fourth class of inhibitor is the RNA-dependent RNA polymerase inhibitor Favipiravir. It 
inhibits the RdRp of influenza virus preventing vRNA replication and transcription (Jin et al. 
2013). It is approved only in Japan and its use is highly restricted (Ison 2015).  
Fifth is Baloxavir Marboxil, an enzyme inhibitor targeting IAV cap-snatching by the viral PA 
subunit. It inhibits the cap-snatching process, thus blocking viral translation (Hayden et al. 
2018). 
Nevertheless, both IAV and IBV can become resistant to these drugs spontaneously or during 
antiviral treatment and some drugs have no activity against IBV. Therefore, novel antiviral 
approaches are needed and DIPs are one option. 
3.3 Defective Interfering Particles (DIPs) 
DIPs are virus mutants that naturally appears when a critical fragment of the viral genome is 
deleted completely or to an extent of non-functionality due to a replication error (Marriott 
and Dimmock 2010). DIPs were defined based on the following criteria 1) they are produced 
and amplified at high multiplicity of infection (MOI) 2) they are replication-deficient and 





are co-infected by DIPs and wt virus, DIPs are produced at the expense of wt virus 4) they 
contain a shortened version of the wt virus genome 5) they are responsible for interference 
(Nayak et al. 1978; Nayak et al. 1985). Any RNA possessing interfering ability is termed 
defective interfering RNA (DI-RNA) and the virus which helps DI-RNA replicate by providing 
the missing viral protein is termed as wt virus (Nayak et al. 1985).  
3.3.1 Overview of the types of DI-RNAs 
DIPs are known to be produced during DNA and RNA virus infection (Perrault 1981) in the 
laboratory and in the host. Viruses for which DIP formation has been described include the 
RNA viruses – Dengue virus, Polio virus, VSV, Semliki forest virus, SARS coronavirus, West 
Nile virus, Influenza virus, the DNA virus – Herpes simplex virus and plant viruses like 
Geminiviruses (Yang et al. 2019). The term DIPs was first proposed in 1970 (Huang and 
Baltimore 1970), although Von Magnus first described particle preparations with inhibitory 
activity as incomplete influenza  virus particles in 1950 (Magnus 1954). 
The generation and amplification of DI-RNAs are autonomous processes. The generation of 
DI-RNAs depends on transcription of viral RNA during a high MOI infection (Nayak et al. 
1978) and two mechanisms for generation of DI-RNAs were postulated. The “jumping 
polymerase” mechanism encompasses the polymerase detaching from one segment or a 
part of the template to another and reattaching to give rise to short mRNA strand ensuring 
to synthesize this mRNA before it further springs. Alternatively, in the “rolling polymerase” 
mechanism the polymerase does not completely separate from the template, instead it rolls 
over to a new site of the template located nearby (Nayak et al. 1985; Nayak et al. 1982). The 
range of genome present in DIPs are listed in Table 3.2 and depicted in Figure 3.4. 
 
Figure 3.4 Types of defective interfering RNAs [adapted from (Vignuzzi and López 2019)] UTR: Untranslated 





Table 3.2 Types of defective interfering RNA (DI-RNA) (Kolakofsky 1976; Leppert 1977): 
Types of DI-RNA DI-RNA arises when Example References 
Simple internal 
deletion 
part of the genome is deleted 
or skipped during replication 
Influenza A virus; 
Flock house virus  
(Perrault 1981; 
Jaworski and Routh 
2017) 
Snap back or 
hairpin 
replicase transcribes part of 
the genome, which snaps back 
and is then used as a template 
 
Vesicular 
stomatitis virus  
(Schubert and 
Lazzarini 1981) 
Copy back or 
Panhandle 
polymerase carries a partially 
made strand and switches 




(van den Hoogen, 
Bernadette G. et al. 
2014; Mura et al. 
2017) 
Mosaic various regions may come 
from same wt virus but in an 
incorrect order 
Tombusvirus (White and Morris 
1994) 
Mutation mutations arise in functionally 
important parts of viral 
genome 
Influenza A virus (Kupke et al. 2019) 
 
3.3.2 Origin of DI-RNA of IAV 
In influenza virus infection a minimum of three types of particles are formed: wt particles, 
defective interfering particles (DIPs) (Nayak 1980), and defective non-interfering particles 
(Hirst and Pons 1973). These particles cannot be substantially separated from each other 
and the ratio with which they are generated may vary between different virus preparations 
and can be determined by plaque assay since non-plaque formers are believed to be 
defective because of the lack of a complete virus genome (Nayak et al. 1985). 
In 1954, IAV was serially passaged in embryonated chicken eggs at a high MOI. As a result, a 
significant decrease in infectivity relative to HA titer was observed. It was due to the 
formation of DIPs (Magnus 1954; Huang and Baltimore 1970). The interfering aspect of DIPs 
was already known from Von Magnus’ studies who infected mice with a fourth undiluted 
PR8 passage and observed complete suppression of wt IAV growth (Magnus 1954). In 
another study the infectious virus load was reduced but provided no protection (Holland and 
Doyle 1973). Though, in general, the stability and level of protection was low, which led to 
inconclusive and unreliable results. To circumvent this issue, DI-RNA sequences were cloned 
with DIPs and wt virus jointly generated by reverse genetics approaches (Duhaut and 





extemporaneously in PR8 infected cells and was cloned using recombinant virus technology. 
It has a large central deletion in segment 1 of IAV which encodes for the PB2 protein. Despite 
the large deletion the terminal sequences required for genome packaging remain intact in 
DI-244. DI-244 RNA has a total length of 395 nucleotides (nt) and has 244 nt at the 3´ end 
and 151 nt at the 5´ end, as depicted in Figure 3.5 (Dimmock et al. 2008).  
 
Figure 3.5 Schematic diagram of DI-244. DI-244 was derived from segment 1 of PR8, which encodes for PB2 
protein. The name stems from the  nt remaining at the ’ end. The total number of nucleotides is shown at 
the right. The nucleotides remaining after central deletion are indicated at the breakpoints [adapted from 
(Meng et al. 2017)]. 
For DI-244 production, eight wt plasmids and DI-244 encoding plasmid are cotransfected 
into 293T cells and supernatants passaged in embryonated chicken eggs (Dimmock et al. 
2008) followed by purification through sucrose gradient centrifugation (Nayak 1980). This 
mixture is treated with UV-irradiation to inactivate wt IAV (Dimmock and Easton 2015) since 
physical separation of DI-RNA and wt virus genome is not possible due to similar particle size 
and density (Nayak et al. 1985). During UV inactivation, wt virus infectivity is selectively 
eliminated due to large size differences: 395 nt for DI-244 as compared to 13,600 nt for wt-
IAV (Dimmock et al. 2008). Long duration of UV-inactivation (about 8 minutes) inactivates all 
its protecting activity and infectivity, called inactive DI-244 (Dimmock et al. 2008).  
3.3.3 Application of DIPs as antivirals  
Dimmock and his colleagues showed that DI-244 DIP preparations are active both 
prophylactically and therapeutically (Dimmock et al. 2012a; Easton et al. 2011; Scott et al. 
2011c, 2011a). For their studies they used DI-244 produced via reverse genetics (Dimmock et 
al. 2008). To demonstrate homologous protection, they admisnistered DI-244 (DIPs) to mice 
jointly with WSN or first infected the animals with IAV and than administered DI-244. The 





infected with virus 4 days before administration of DIPs and was completely lost when 
viruses was added 7 days before DIPs (Dimmock and Easton 2014; Dimmock et al. 2008).  
The ratio of DIP to wt virus plays an crucial role in DIP anti-viral activity. As infection 
progresses, the number of infectious wt IAV particles increases significantly where the 
amount of DIPs administered becomes insufficient to influence the infection. A concern from 
the preclinical studies of DI-244 was that replication of wt virus was reduced but not 
completely repressed. Ferrets are important animal models of IAV infection, and are used to 
evaluate vaccines. In a ferret study, animals were protected from infection with the 
pandemic A/California/04/2009 virus when DI-244 was given 2 hours prior to wt IAV 
infection and were immune to reinfection with A/Cal (Dimmock et al. 2012b).  
Besides protection against homologous viruses, DI-244 was shown to protect in vivo against 
heterologous viruses such as B/Lee/40 (IBV) (Scott et al. 2011a) and pneumonia virus of mice 
(PVM) (Easton et al. 2011). In these studies, coadministration of DI-244 with IBV protected 
the animals from clinical disease and pre-treatment of mice with DI-244 augmented the 
efficiency of protection (Scott et al. 2011a). Similarly, pre-treatment with a single dose of DI-
244 protected mice from PVM (Easton et al. 2011). A comparative study of heterologous 
protection from PVM and homologous protection from IAV showed that homologous 
protection was 5-fold more effective. This difference could be due to different mechanisms 
underlying the two types of protection (Dimmock and Easton 2014), which is summarized in 
below Figure 3.6. The mechanisms are defined later in detail. 
 
Figure 3.6 Overview of homologous and heterologous protection. DI-244 RNA protects from homologous 
challenge with IAV by replication interference and stimulation of the IFN system while protection against 
heterologous challenge is solely due to stimulation of the IFN system. [Adapted from (Easton et al. 2011)] 
DI 244/PR8 
virus
Homologous in vivo 
protection (by replication 
interference)
IAV
Heterologous in vivo 








These studies prove, that DI-244 1) converts a potentially lethal infection into an avirulent 
infection 2) protection is possible during a substantial time window with a lower 
concentration of DIPs 3) is more effective than a non-clonal DI virus in providing protection 
(Dimmock and Easton 2014). However, these studies also demonstrated that DI viruses 1) 
are ineffective and could be diluted when not administered systematically targeting specific 
areas of organ (Dimmock and Easton 2015)  2) comprised of complex mixtures of different 
DI-RNAs (Jennings et al. 1983; Duhaut and Dimmock 1998) 3) unavoidably contained 
mixtures of defective RNAs that did not interfere with the replication of wt virus (Barrett et 
al. 1984). 4) heterogeneity led to reproducibility issues and prevented that solid conclusions 
on the potential of DIPs as antiviral could be drawn (Dimmock and Easton 2014).  
Wasik and colleagues reported an approach to reduce genetic variablity of DIPs (Wasik et al. 
2018). DI-244 was replicated in a designer cell line, AGE1.CR.pIX, originated from Muscovy 
duck and known to propagate influenza viruses (Lohr et al. 2009) faster than primary chicken 
cells (Jordan et al. 2009). The wt virus used to amplify DIPs was characterized to be free of 
deletions in other segments. This approach allowed DIP production under well-controlled 
conditions but still relied on the use wt IAV (Wasik et al. 2018). This limitation could be 
addressed by generating cell lines that provide these viral proteins in trans that are not 
encoded by DIPs because the respective open reading frames were destroyed during DI-RNA 
generation.  
3.3.4 Antiviral mechanism of DIPs 
Several mechanisms have been proposed for the inhibition of influenza virus infection by 
DIPs including replication interference, IFN induction, viral persistence and virulence 
modulation (Vignuzzi and López 2019) Figure 3.7. Replication interference and IFN induction 
will be discussed below. Viral persistence, the mechanism by which DIPs establish persistent 
infection in cell cultures and re-initiate replication when cells become infected with wt virus. 
It was found that persistently infected cell cultures, at a later passage, were resistant to 
homologous virus infection while producing little or no virus. (De and Nayak 1980). However, 
it is known that the amounts of DIPs remain constant during some of these infections 
(Moscona 1991). Virulence modulation, the mechanism by which DIPs reduce pathogenesis 
by mediating humoral immune responses, rather than auto-interference with replication of 






Figure 3.7 Overview of mechanisms that may underly DIP antiviral activity. [inspired by (Vignuzzi and López 
2019)] 
3.3.4.1 Replication Interference  
Replication interference is defined as DIPs outcompeting wt virus for resources required for 
genome replication (Pathak and Nagy 2009). Replication interference depends on the size of 
the deletion present in the DI-RNA (Jennings et al. 1983; Nayak et al. 1985; Frensing et al. 
2013) since smaller DI-RNAs replicate faster than larger ones and can thus compete with the 
corresponding wt RNAs with higher efficiency (Nayak et al. 1985; Marriott and Dimmock 
2010). DI-RNAs derived from genomic segments 1, 2 and 3 (encoding the polymerase 
proteins) and harbouring internal deletions are frequently studied (Davis and Nayak 1979; 
Jennings et al. 1983). The ’ end of these DI-RNAs must retain at least 150 nt in order to 
ensure DI-RNA replication (Duhaut and Dimmock 2002). However, DI-RNAs without 
deletions but harbouring multiple mutations can exist in IAV preparations and may exhibit 
strong antiviral activity via partially understood mechanisms (Kupke et al. 2019).  
The ratio between DIP and wt IAV critically determines replication interference and it has 
been suggested that based on RNA copy numbers, DIPs have to be administered at a 10,000 
to 100,000-fold excess relative to wt virus in order to exert potent antiviral activity via 
replication interference (Dimmock and Easton 2014). Finally, replication interference is most 
potent when the wt viruses are examined from which the DIPs were derived but weak or 
absent when heterologous viruses are studied (Marriott and Dimmock 2010). More 
specifically, replication interference of any IAV DI-RNAs probably extends to all wt IAVs. 


















DIPs suppress replication of wt virus (Figure 3.8). Besides genome replication, DIPs are 
known to exert antiviral activity by affecting packaging steps of IAV. The smaller DI-RNAs are 
preferentially packaged into new virus particles in comparison to wt RNAs (Liao et al. 2016). 
DI-244 RNA interferes with replication of several genomic RNAs in cells infected with IAV and 
mutation of start codons of DI-244 has no effect on interference indicating inhibition is 
independent of any protein product (Meng et al. 2017). Mutation forms of DIPs, OP7 virus, 
reduced HA and infectious titers when co-infected with wt virus by interfering with virus 
replication (Kupke et al. 2019). 
 
 
Figure 3.8. DIPs suppress the cycle of wt viruses. The red arrows indicate the inhibitory effect of DIPs. During 
co-infection with wt virus, DIPs prevent wt virus A-C) from invading cells by binding to cell surface receptors D) 
replication cycle by competing for resources E) RNAs from packaging into progeny virions as DI RNAs being 
shorter are preferentially packaged F) at release step (Yang et al. 2019) 
3.3.4.2 Interferon induction 
Inhibition of heterologous viruses by DIPs suggested that replication interference is not the 
sole mechanism underlying DIP antiviral activity and pointed towards activation of innate 





mice were observed to be weakly protected by DI-244 against PVM, although protection 
against WSN infection was robust (Easton et al. 2011). It was even suggested that DI-244 
may protect against all type I IFN-sensitive respiratory viruses in the presence of a functional 
IFN system. However, induction of IFN by DIPs might not be limited to type I IFN (Easton et 
al. 2011; Scott et al. 2011a) since type III IFN was shown to be important for  protection 
against IAV and IBV infection in vivo (Mordstein et al. 2010).  
3.3.5 The interferon system 
The innate immune system serves as the first line of defence against pathogens and 
macrophages, dendritic cells, neutrophils, eosinophils, natural killer (NK) cells are important 
innate immune cells. The IFN system is a essential component of innate immunity and 
essential for the defence against viral infections. IFNs were discovered in 1957 by Isaacs & 
Lindenmann as a substance produced by cells that interferes with influenza virus infection 
(Isaacs et al. 1957; Schneider et al. 2014; Isaacs and Lindenmann 1957). IFNs are small 
proteins secreted by cells (Lengyel 1982) following the recognition of pathogens (Wu and 
Chen 2014). 
3.3.6 Sensors and signal transducers of the interferon system  
The IFN system recognises pathogen associated molecular patterns (PAMPs) using different 
pattern recognition receptors (PRRs). PRRs are either endosomal transmembrane proteins or 
cytosolic proteins and PRRs recognizing nucleic acids are grouped into three types: Toll-like 
receptor (TLR),  cyclic GMP-AMP synthase (cGAS) and RIG-I-like receptors (RLR) (Fensterl et 
al. 2015). Binding of PAMPs to these PRRs induces conformational changes in the PRRs that 
result in activation of downstream adaptor molecules.  
TLRs are transmembrane proteins containing multiple leucine-rich repeat domains 
responsible for recognition of PAMPs, such as dsRNA (TLR3) or ssRNA (TLR7, TLR8) (Xagorari 
and Chlichlia 2008; Gay et al. 2014). They are localized at the plasma membrane or in 
endosomes and thus mainly responsible for detection of extracellular nucleic acids (Gay et 
al. 2014). The cytosolic cGAS acts as a DNA detector, which produces cyclic dinucleotides 
(2'3'-cGAMP) from ATP and GTP upon binding of DNA (Cai et al. 2014).The RLR family 
consists of three members that include the retinoic acid inducible gene I (RIG-I), melanoma 
differentiation factor 5 (MDA5), and Laboratory of Genetics and Physiology gene 2 (LGP2) 





the ends (Yoneyama et al. 2015; Weber et al. 2013; Goubau et al. 2014) whereas MDA5  
recognises long dsRNAs (Kato et al. 2008). Both RIG-I and MDA5 signal to mitochondrial 
antiviral signalling protein (MAVS) (Seth et al. 2005). PRR signalling ultimately activates 
interferon regulatory factor 3 (IRF3) to induce IFN-β gene expression (Honda et al. 2006; 
Paun and Pitha 2007). Subsequently IFN-β stimulates a first wave of ISG transcription, 
including IFN-inducible transcription factor IRF7. Eventually IRF7 activates various IFN-α 
subtypes, thereby mediating second wave of ISG transcription. (Lazear et al. 2019). In 
addition to IFN-α and IFN-β, IRF3 and/or IRF7 induces IFN-λ (Osterlund et al. 2007), whereas 
IRF1 induces IFN-λ1 (Odendall et al. 2017)   
Indirect evidence from quantification of interferon-inducing and defective particles from DIP 
preparations indicated that DIPs alone do not induce IFN (Ngunjiri et al. 2012). Another 
study showed mini viral RNAs (mvRNAs) bind to RIG-I and considerably induce higher IFN 
expression in comparison to full-length genome or DI-RNA (Te Velthuis et al. 2018). RIG-I 
plays a crucial role in sensing viral infection and commencing IFN expression (Pichlmair et al. 
2006). RIG-I preferentially associates with DI-RNAs in comparison to the corresponding wt  
RNAs in influenza-infected cells (Baum et al. 2010). RIG-I promotes disassembly of viral 
polymerase complex by binding to ’ppp-ds RNA panhandle structure of PB2 exhibiting 
direct antiviral activity (Weber-Gerlach and Weber 2016).  
3.3.6.1 Types of interferons and receptors 
Interferons (IFN) are classified into three subtypes: type I (IFN- α, β, ε, κ, ω, ζ [mice]), type II 
(IFN-γ) and type III (IFN-λ) based on amino acid sequence and type of receptor they use for 
signalling. IFN-α and IFN-β signal through a heterodimeric IFN-alpha-receptor 1 (IFNAR1) or 
IFN-alpha-receptor 2 (IFNAR2) complex (Pestka et al. 2004). All tissue cells are capable of 
producing IFN-α and β, but a huge amount is produced by plasmacytoid dendritic cells 
(pDCs) and macrophages during influenza virus infection (Siegal et al. 1999).Type II IFN 
consists of single molecule, IFN-γ, produced by immune cells. It signals through homodimeric 
IFN-gamma-receptor 1 (IFNGR1) and IFN-gamma-receptor 2 (IFNGR2) (Pestka et al. 1997).  
Type III IFNs, namely IFN-λ , IFN-λ , IFN-λ  are the most recently discovered members of the 
IFN group (Kotenko et al. 2003; Sheppard et al. 2003). IFN-λ is produced by pDCs and 





interleukin-10 receptor 2 (IL-10R2) and IFN-lambda-receptor (IFNLR) (Schneider et al. 2014). 
Type III IFN signalling is restricted to epithelial cells (Sommereyns et al. 2008). 
3.3.6.2 The JAK/STAT pathway 
In the 1990s a pathway for IFN-induced gene expression was found to be a important one, 
commonly known as the JAK-STAT signalling pathway (Velazquez et al. 1992; Darnell et al. 
1994). Upon binding of IFN to their cell-surface receptors a signalling cascade is triggered 
leading to drastic changes in the properties of cells, the foremost being induction of an 
antiviral state (Stark and Darnell 2012).  
 
 
Figure 3.9. The JAK-STAT signalling pathway. Binding of IFN to their respective receptors induces 
phosphorylation of Janus kinase (JAK) and tyrosine kinase (TYK). This leads to phosphorylation of signal 
transducer and activator of transcription (STAT). The STATs important for type I and III IFN signalling then bind 
to the IFN-regulatory factor 9 (IRF9) to form IFN-stimulated gene factor 3 (ISGF3) complex. The STAT1 
homodimers crucial for type II IFN signalling form the IFN-γ activation factor (GAF) complex. Both complexes 
translocate to the nucleus to induce antiviral genes (Schneider et al. 2014). 
Binding of type I and type III IFNs to their receptors trigger phosphorylation of Janus kinase 1 
(JAK1) and tyrosine kinase 2 (TYK2), which in turn phosphorylates the receptors at specific 
intracellular tyrosine residues. Subsequently, this leads to the phosphorylation of signal 
transducers and activators of transcription 1 and 2 (STAT 1 and 2). STAT1 and 2 form 





stimulated gene factor 3 (ISGF3) complex (Schindler et al. 1992; Stark and Darnell 2012). 
Binding of type II IFN dimers to their receptors lead to phosphorylation of JAK1 and JAK2 
tyrosine kinases and transphosphorylation of receptor chains then leads to phosphorylation 
of STAT1. Phosphorylated homodimers of STAT1 form the IFN-gamma activation factor 
(GAF). Both ISGF3 and GAF translocate into the nucleus and induce genes regulated by IFN-
stimulated response elements (ISRE) and gamma-activated sequences (GAS) respectively, 
resulting in the expression of antiviral genes (Schneider et al. 2014; Wang et al. 2017) (Figure 
3.9) 
3.3.6.3 Signal Transducer and Activator of Transcription (STAT) 
There are seven STAT proteins in mammals STAT 1, STAT2, STAT 3, STAT 4, STAT 5a, STAT5b, 
and STAT6 (Schindler et al. 1992; Darnell et al. 1994). STATs belongs to a family of 
transcription factors that are activated in response to cytokines, growth factors and certain 
peptides (Levy and Darnell 2002). STAT1 is phosphorylated in response to IFN binding to 
their receptors (Fu et al. 1992) but can also be acetylated by dephosphorylation of tyrosine 
and methylated by methyl transferase of STAT1 inactivator leading to increased binding 
affinity (Najjar and Fagard 2010). Studies report that after IFN-α treatment, STAT  was first 
recruited via its Src homology region 2 (SH2) domain to phosphotyrosine and then promotes 
STAT1 phosphorylation (Stark et al. 1998; Park et al. 2000). In the absence of STAT1, STAT2 
interacts with IRF9 forming an ISGF3 complex to stimulate ISG expression (Fink and 
Grandvaux 2013). In STAT1-knockout cells, IFN-γ was found to regulate a large panel of 
genes by mediating via alternative pathways used by their receptors in primary cells (Gil et 
al. 2001).  
3.3.7 Interferon-stimulated genes  
Interferon-stimulated genes (ISGs) are liable for antiviral, antitumor and immunosuppressive 
properties of IFN. IFN induces the expression of roughly 400 genes, many of which encode 
proteins with antiviral activity that are responsible for the IFN-induced antiviral state 
(Iwasaki and Pillai 2014). ISGs with anti-influenza activity are listed in the Table 3.3 
ISGs control viral, bacterial, and parasitic infection by directly targeting pathogens or cellular 
pathways required for pathogen multiplication (Schneider et al. 2014). Importantly, PRRs, 





thus augment the IFN response. ISGs with antiviral activity can block early or late steps of 
the viral replication cycle (Schneider et al. 2014). For example, IFN-induced transmembrane 
proteins (IFITM) block virus entry (Brass et al. 2009), while viperin inhibits virus budding 
(Wang et al. 2007).  
The murine Myxovirus resistance gene (Mx1) was the first antiviral gene identified and is 
considered to be highly important for countering IAV infection. Human cells express Mx1 
(also termed MxA) and Mx2 (also termed MxB) proteins. Both are IFN-induced and belong to 
the family of GTPases. They block an early post-entry step occurring prior to viral genome 
replication (Schneider et al. 2014). Mx1 acts against IAV while Mx2 potently inhibits HIV-1 
and HIV-2 (Goujon et al. 2013). Mx1 traps the nucleocapsid of IAV and prevents it from 
reaching the nucleus (Zimmermann et al. 2011). Mx1 consists of a stalk region and a GTPase 
effector domain which both are essential for self-oligomerization and formation of a ring-like 
structure. This structure plays an important role in antiviral activity against IAV (Gao et al. 
2010; Haller et al. 2010; Haller et al. 2015; Villalón-Letelier et al. 2017). Mx1 is 
transcriptionally upregulated by type I and type III IFN. Infection of STAT1-deficient cells  
with NS1-deficient IAV did not induce Mx1 gene expression, indicating that Mx1 expression 
requires STAT1 signalling and cannot be triggered upon virus infection (Holzinger et al. 
2007). 
Table 3.3 Anti influenza virus-activity of interferon-stimulated genes [adapted from (Iwasaki and Pillai 2014)] 
ISGs Control mode Reference 
 OAS Inhibits virus by degrading viral RNA and blocking 
translation of viral mRNAs 
Senses foreign RNA and produces ’- ’ adenylic acid 
which activates RNaseL that cleaves vRNA 
(Silverman 2007) 
PKR Blocks translation, activates the NF-κB pathway, 
Phosphorylates the α-subunit of EIF α, and stabilizes 
IFN-α and IFNβ mRNA 
(Kumar et al. 1994; 
Balachandran et al. 
2000; Sadler and 
Williams 2007; Schulz 
et al. 2010) 
CH25H Affects virus at host-membrane fusion, protein 
maturation of viral structural proteins and of viral 
replication enzymes 
Blocks viral fusion by converting cholesterol to a soluble 
25-hydroxycholesterol 
(Liu et al. 2012; Blanc 
et al. 2013) 
IFITM1-3 Inhibits endocytic fusion events 
 
(Brass et al. 2009; 
Bailey et al. 2012; Jia 





OAS, ’- ’-oligoadenylate synthetase; RNaseL, latent RNase; PKR, protein kinase R; EIF α, eukaryotic translation 
initiation factor α; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B-cells; CH25H, cholesterol 
25 hydroxylase; IFN, interferon; IFITM, IFN-induced transmembrane; ISG, interferon stimulated gene; TRIM, 
tripartite motif-containing protein; MOV10, Moloney leukemia virus 10 homolog; SPRY, SPla and the RYanodine 
Receptor; ANP32A, acidic nuclear phosphoprotein 32 family member A; CD274, programmed cell death 1 
ligand 1 (PDL-1); TLR3, Toll-like receptor 3; TRIF, Toll/interleukin-1 receptor domain-containing adaptor 






ISGs Control mode Reference 
ISG15 Targets viral proteins that are newly translated for 
ubiquitination 
(Lenschow et al. 
2007; Durfee et al. 
2010) 
Viperin Forms lipid rafts from which virus buds and prevents 
release of influenza virus 
(Wang et al. 2007; 
Hinson and Cresswell 
2009a, 2009b) 
ISG20 Suppresses viral polymerase and exhibits exonuclease 
activity essential for anti-IAV activity 
(Qu et al. 2016) 
TRIM25 Binds vRNPs in the nucleus of infected cells and restrict 
the influenza replication. 
Inhibits the RNA chain elongation by restricting RNA 
movement in polymerase complex 
(Meyerson et al. 
2017) 
MOV10 Binds to the viral NP to prevent its import into the 
nucleus 
(Zhang et al. 2016) 
TRIM56 Inhibits replication of virus-infected cells in the nucleus 
independent of ubiquitin ligase activity where its C-
terminal tail suppresses viral RNA synthesis 
(Liu et al. 2016; 
Villalón-Letelier et al. 
2017) 
SERPINE1 Reduces infectivity of progeny virus by targeting a 
plasminogen activator inhibitor 1 (PA1-1) that inhibits 
IAV glycoprotein cleavage  
(Dittmann et al. 2015) 
TRIM41 Interacts with nucleoprotein of IAV through target 
binding site (SPRY domain) to inhibit the infection  
(Patil et al. 2018) 
ANP32A Overcomes viral polymerase host (avian) restriction by 
promoting interaction with the viral polymerase  
 (Domingues and Hale 
2017) 
CPSF4 Affects both viral replication and IAV-associated type I 
IFN secretion by interacting with viral NS1  
(Dubois et al. 2019) 
SMARCA2 Facilitates antiviral activity of MxA against IAV by being 
dependent on ISGs   
(Dornfeld et al. 2018) 
TRIM38 Regulates negatively TLR3-mediated IFN-β signalling by 
targeting TRIF 
(Xue et al. 2012) 
CD274 Accelerates influenza virus clearance and infection 
recovery by blockade in the airways 
(McNally et al. 2013) 






Seasonal influenza is responsible for half a million deaths every year. Influenza viruses 
rapidly develop resistance against antivirals and vaccines need to be constantly adapted to 
the circulating viruses. Therefore, novel antiviral strategies to combat influenza are urgently 
needed. One novel approach is the use of defective viral particles that harbour deletions in 
essential genes and interfere with wt virus infection. Such particles are called defective 
interfering particles (DIPs) and exhibit potential as therapeutic and prophylactic agents. 
However, so far, production of DIPs was dependent on the use of wt viruses as helper 
viruses, which raises safety concerns. Moreover, it was incompletely understood how DIPs 
inhibit influenza virus infection. These questions were to be addressed within the present 
thesis: 
The first aim of this thesis was to develop a system for production of DIPs in the absence of 
wt virus. Specifically, it was to be investigated whether expressing the viral polymerase 
protein PB2 in cells allows amplification of DIPs harbouring a deletion in the genomic 
segment encoding for PB2.  
The second aim of this thesis was to obtain insights into how DIPs inhibit influenza virus 
infection. Most importantly, it was to be determined to what extend interference with viral 
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Individual contribution: In the following manuscript I conducted experiments for Figure 1 A, 
B and C; “Stable expression of active PB  protein in T and MDCK cells.” for Figure ; 
“PB opt stably expressed in T cells is active.” for Figure  D; “Codon optimization of PB2 
results in increased DIP production.” and for Figure  A; “DI-244 produced in PBopt 
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Influenza virus infection poses a serious threat to human health. Defective interfering 27 
(DI) RNAs result from errors during viral RNA replication and suppress influenza virus 28 
infection. DI RNAs packaged into defective interfering particles (DIPs) might allow for a 29 
novel approach to antiviral therapy. However, mutations required for converting a viral 30 
RNA into a DI RNA and the mechanism underlying DI RNA antiviral activity are 31 
incompletely understood. Here, we show that any central deletion is sufficient to convert 32 
a viral RNA into a DI RNA and that antiviral activity is inversely correlated with DI 33 
RNA length under conditions which disfavor inhibition of influenza virus infection by 34 
DIP-dependent induction of the IFN system. When full DIP-mediated induction of the 35 
IFN system was allowed before influenza virus infection, it was found to be the major 36 
contributor to DIP antiviral activity while DI RNA length played no detectable role. 37 
Notably, both DIPs and influenza virus triggered expression of IFN-stimulated genes 38 
(ISGs) while only virus stimulated robust expression of IFN, suggesting differences in 39 
DIP- and influenza virus-mediated activation of the effector functions of the IFN system. 40 
Collectively, our results support a model positing that DI RNAs inhibit viral infection by 41 
outcompeting wt RNAs for resources required for RNA replication but demonstrate 42 














The annually recurring influenza epidemics are a major source of global morbidity and 53 
mortality and intermittent pandemics can have even more severe consequences (Paules and 54 
Subbarao, 2017). Influenza therapy and vaccination are available but suffer from serious 55 
shortcomings (Paules and Subbarao, 2017). The success of influenza therapy with currently 56 
licensed drugs, which target the viral proteins neuraminidase (NA), matrix protein 2 (M2) or 57 
polymerase acidic protein (PA), can be compromised by resistance development (Han et al., 58 
2018). Moreover, vaccines against epidemic influenza need to be annually adjusted to the 59 
viruses expected to circulate during the next influenza season and offer little or no protection 60 
against emerging pandemic viruses (Paules and Subbarao, 2017). Thus, the identification of 61 
novel targets and strategies for antiviral intervention is an important task. 62 
 Influenza viruses contain a segmented, negative sense RNA genome. The genomic 63 
segments are replicated by the viral polymerase, which consists of the subunits polymerase 64 
basic protein 1 (PB1), PB2 and PA (Te Velthuis and Fodor, 2016). The error rate of the viral 65 
polymerase is high and can result in the synthesis of genomic segments that harbor deletions 66 
(Davis et al., 1980; Davis and Nayak, 1979; Dimmock and Easton, 2014, 2015; Nakajima et 67 
al., 1979; Nayak et al., 1982; Nayak et al., 1978). Some of these defective segments interfere 68 
with the amplification of wt segments and are thus termed defective interfering (DI) RNAs 69 
(Davis et al., 1980; Davis and Nayak, 1979; Dimmock and Easton, 2014, 2015; Nakajima et 70 
al., 1979; Nayak et al., 1982). Packaging of DI RNAs into viral particles results in the 71 
formation of DI particles (DIPs), which suppress wt influenza virus spread (Dimmock and 72 
Easton, 2014, 2015). It has been proposed that DIPs suppress influenza virus infection by 73 
interfering with genome replication (a process subsequently termed replication interference) 74 
and by inducing interferon (IFN) (Baum et al., 2010; Dimmock and Easton, 2014, 2015; 75 
Frensing et al., 2014; Ngunjiri et al., 2013; Ngunjiri et al., 2012; Perez-Cidoncha et al., 2014; 76 





relative contribution of replication interference and IFN induction to DIP antiviral activity is 78 
unknown. 79 
 We recently developed a cell culture system that allows production of genetically 80 
defined DIPs based on reverse genetics and a cell line complementing defects in influenza A 81 
virus (IAV) genomic segment 1 (Bdeir et al., 2019). Here, we used this system as well as a 82 
mini-replicon assay (Zimmermann et al., 2011) to analyze the contribution of replication 83 
interference and IFN induction to antiviral activity of DIPs. We report that in the mini-84 
replicon assay any central deletion in segment 1, 2 or 3 converts these segments into DI 85 
RNAs, which suppress replication of diverse target segments. Inhibitory activity of these DI 86 
RNAs was inversely correlated with segment length and a similar correlation was seen in the 87 
context of DIPs and IAV infection under conditions which disfavored IAV inhibition by DIP-88 
dependent induction of the IFN system. If induction of the IFN system was allowed before 89 
IAV infection, it largely accounted for DIP antiviral activity. Finally, DIPs robustly induced 90 
ISG but not IFN expression, indicating that IAV and DIPs may differ in the activation of the 91 
effector functions of the IFN system. Our results suggest that although interference with 92 
genome replication contributes to DIP antiviral activity, the induction of IFN is the major 93 
determinant of suppression of virus infection by DIPs. 94 
 95 
RESULTS  96 
 97 
DI-244 inhibits segment replication in a mini-replicon assay and inhibition is 98 
independent of the truncated PB2 open reading frame 99 
We first investigated whether a previously described IAV mini-replicon assay (Zimmermann 100 
et al., 2011) is suitable to detect inhibition of IAV genome replication by a prototypic 101 
segment 1-derived DI RNA, DI-244 (Dimmock et al., 2008). This assay is based on a firefly 102 





amplified in cells upon coexpression of the constituents of the viral polymerase complex, 104 
PB2, PB1, PA, and the viral NP protein (Zimmermann et al., 2011). Transfection of 293T 105 
cells with plasmids encoding the mini-genome reporter segment and the IAV proteins 106 
mentioned above resulted in luciferase activities in cell lysates that were approximately 107 
1,000-fold higher than those measured in cells transfected with the reporter alone or 108 
transfected with the full set of plasmids except the PB2 encoding plasmid (Figure 1A). 109 
Moreover, cotransfection of two different amounts of DI-244 encoding plasmid resulted in a 110 
concentration dependent decrease in luciferase activity, indicating that DI-244 inhibited 111 
replication of the reporter segment (Figure 1A). This inhibitory activity was also observed 112 
when the PB2 start codon in DI-244 and two subsequent ATGs (positions 11 and 28) were 113 
mutated (Figure 1B). In contrast, transfection of expression plasmid pCAGGS containing the 114 
truncated PB2 ORF of DI-244 or empty pCAGGS did not reduce luciferase signals (Figure 115 
1B). These results indicate that inhibition of segment replication by DI-244 can be visualized 116 
in the mini-replicon assay and does not require expression of truncated PB2. 117 
 118 
Inhibitory activity of segment 1, 2 and 3-derived DI RNAs is inversely correlated with 119 
RNA length and is independent of the target segment 120 
 It is believed that the short length of DI-244 as compared to wt segment 1 results in faster 121 
amplification of DI-244 and ultimately in suppression of amplification of the wt segment 122 
(Dimmock and Easton, 2014, 2015).  If correct, one would assume that the length of a DI 123 
RNA is a major determinant of antiviral activity. We explored this possibility by investigating 124 
the capacity of a set of ten segment 1-derived RNAs with nested central deletions to inhibit 125 
segment amplification in the mini-replicon assay. All RNAs tested exerted inhibitory activity 126 
and an inverse correlation between RNA length and inhibitory activity was observed (Figure 127 
1C, Table S1). Moreover, further shortening of DI-244 did not augment inhibitory activity 128 





replication. In sum, our results show that the ability of segment 1-derived DI RNAs to block 130 
replication of a wt segment is dependent on the DI RNA length. 131 
 We next explored whether the inverse correlation between length and inhibitory 132 
activity is also observed for segment 2- and 3-derived DI RNAs. For this, we introduced 133 
central, nested deletions in segment 2 and 3 and investigated inhibitory activity in the mini-134 
replicon system. As for segment 1-derived RNAs, all segment 2- and 3-based RNAs with 135 
deletions exerted inhibitory activity and inhibition inversely correlated with RNA length, 136 
although this correlation was more pronounced for segment 2 as compared to segment 3 137 
(Figure 1D, Table S1).  138 
 Next, we examined whether the segment 1-, 2- and 3-derived DI RNAs with the 139 
largest deletion (constructs DI-244 (segment 1, S1), DI-156 (segment 2, S2), DI-178 (segment 140 
3, S3), Table S1) were able to efficiently suppress replication of different IAV segments or 141 
were mainly active against segment 8, which was so far employed in the mini-replicon assay. 142 
For this, we added the 5  and 3  ends of segments 1, 2, 4, 6, and 7 to the firefly luciferase 143 
sequence and tested the amplification of these reporter segments in the mini-replicon assay. In 144 
the absence of DI RNAs, all segments were efficiently amplified, as demonstrated by high 145 
luciferase activity in lysates of cells coexpressing PB2, PB1, PA and NP (Figure 1E). 146 
Cotransfection of two different amounts of segment 1-, 2- or 3-derived DI RNAs reduced 147 
replication of all reporter segments efficiently and in a concentration dependent manner 148 
(Figure 1E). Thus, in the mini-replicon assay, introduction of a deletion into an IAV genomic 149 
segment is sufficient to convert it into a DI RNA and length and inhibitory activity of these 150 
DI RNAs are inversely correlated. 151 
 152 
Inverse correlation between anti-IAV activity of DIPs and DI RNA length 153 
 We recently reported a cell culture system for production of DIPs in the absence of helper 154 





PB2 protein (Bdeir et al., 2019). We employed this system to generate DIPs with nested 156 
deletions in segment 1 and assessed their ability to inhibit infection of MDCK cells with 157 
A/PR/8/34 (PR8). We found that DI-244, which contains the smallest DI RNA, inhibited PR8 158 
infection with the highest efficiency and that inhibitory activity of DIPs decreased as DI RNA 159 
length increased (Figure 1F). Thus, an inverse correlation between DI RNA length and 160 
inhibitory activity observed in the mini-replicon assay could be confirmed in the context of 161 
DIPs, at least under the conditions tested. 162 
 163 
Preincubation of target cells with DI-244 increases antiviral activity 164 
It has been reported that DIPs can block viral infection by stimulating the IFN system (Scott 165 
et al., 2011a, b). Therefore, we sought to clarify whether induction of the IFN system could 166 
contribute to DI-244 antiviral activity in MDCK cells. Trypsin is used for A/PR8/34 167 
activation but can inactivate IFN  (Figure 2A) (Seitz et al., 2012) and can thus cofound 168 
analyses of IAV inhibition by the IFN system. Therefore, we switched to A/WSN/33 (WSN) 169 
as challenge virus and WSN-derived DIPs, since WSN can replicate trypsin-independently in 170 
cell cultures containing fetal bovine serum (FBS) (Goto and Kawaoka, 1998).  To obtain first 171 
insights into a potential role of the IFN system in DIP antiviral activity,  we reasoned that if 172 
induction of the IFN system was a major determinant of DIP antiviral activity, then time-of-173 
DIP addition to target cells should have a major impact on the efficiency of IAV inhibition by 174 
DIPs. Thus, addition of DIPs and virus to target cells at the same time should preclude the 175 
establishment of a DIP induced antiviral state prior to IAV infection. In contrast, addition of 176 
DIPs at 24 h before virus should allow for establishment of such an antiviral state and might 177 
thereby boost DIP antiviral activity. Preincubation of target MDCK cells with DI-244 for 24 h 178 
indeed increased DIP antiviral activity as compared to simultaneous addition of DI-244 and 179 
IAV, especially when high doses of DI-244 were analyzed (Figure 2B, left panel). 180 





panel), indicating that the enhanced antiviral activity of DI-244 upon 24 h preincubation with 182 
target cells was likely not due to induction of IFN  or another trypsin-sensitive antiviral host 183 
cell protein. 184 
  185 
DI-244 induces anti-IAV activity in A549 cells in a STAT1-independent fashion 186 
In order to more directly assess the contribution of the IFN system to DI-244 antiviral 187 
activity, we used A549 wt cells and A549 cells which lack STAT1 (signal transducer and 188 
activator of transcription 1, STAT1-/-) and are thus defective in IFN-induced signaling. 189 
Confirmatory experiments revealed that IFN , IAV and DI-244 strongly upregulated MX1 190 
expression in A549 wt but not STAT1-/- cells, in keeping with a defective JAK/STAT 191 
signaling pathway (Figure 2C). Addition of undiluted and 1:10 diluted DI-244 to A549 cells 192 
at 24 h before infection with WSN resulted in 100 -fold higher antiviral activity as compared 193 
to DI-244 added at the same time as virus (Figure 2D), confirming and extending the data 194 
obtained with MDCK cells. Unexpectedly, addition of undiluted DIP to A549 STAT1-/- cells 195 
still resulted in high antiviral activity (Figure 2D), although 10-fold diluted DI-244 showed 196 
markedly reduced antiviral activity in STAT1-/- cells as compared to wt cells. In contrast, 197 
inhibition of vesicular stomatitis virus (VSV) infection by DI-244 was completely dependent 198 
on STAT1, independent of the DIP dose used (Figure 2D). Finally, we asked whether the 199 
antiviral activity of DIPs still depends on the DI RNA length if DIPs are added to cells before 200 
virus. In contrast to what was observed with MDCK cells in the presence of trypsin, all DIPs 201 
with nested deletions in segment 1 inhibited WSN infection of A549 wt cells with similar 202 
efficiency (Figure 2E and data not shown), indicating that the contribution of replication 203 
interference to DIP antiviral activity was minor or absent under those conditions. Collectively, 204 
our findings indicate that DIPs can induce robust, partially STAT1-independent anti-IAV 205 
activity that is not determined by DI RNA length and markedly more potent than DIP-206 





DI-244 induces robust expression of ISGs but not IFN 208 
In order to understand how DIPs, activate the IFN system, we compared DIP- and IAV-209 
mediated stimulation of IFN expression. For this, an IFN bioassay was employed that was 210 
based on VSV, a highly IFN-sensitive virus. A549 or A549 STAT1-/- cells were incubated 211 
with IAV, VSV or DI-244 for 24 h, the supernatants collected and heat and acid treated to 212 
inactivate viral particles but not IFN, which is known to display a certain heat and acid 213 
stability. Subsequently, the supernatants were added to target cells for 16-18 h followed by 214 
infection of A549 target cells with VSV and quantification of infection. For standardization, 215 
A549 cells were incubated with recombinant IFN , infected and infection efficiency 216 
quantified. Supernatants from IAV exposed A549 wt cells but not A549 STAT1-/- cells 217 
potently inhibited VSV infection (Figure 3A), indicating that IAV induced production of IFN 218 
in a STAT1-dependent fashion, as expected. Similar findings were made with supernatants 219 
from VSV exposed cells but antiviral activity was independent of STAT1 expression (Figure 220 
3A), again in agreement with published data (Basu et al., 2006). Finally, and unexpectedly, 221 
supernatants from A549 wt cells exposed to DI-244 were not inhibitory and the same finding 222 
was made for supernatant from DI-244 treated A549 STAT1-/- cells, indicating that IFN 223 
induction by DI-244 was low or absent. 224 
 The ability of DI-244 to inhibit IAV and VSV infection without inducing IFN posed 225 
the question how DI-244 alters gene expression in target cells to block infection. To address 226 
this question, A549 cells were either incubated with control supernatants or supernatants 227 
containing DI-244 or IAV and subjected to RNAseq analysis. PR8 was employed for these 228 
studies, in order to limit viral replication to a single cycle (since no trypsin was added). 229 
Neither PR8 nor DI-244 induced the expression of IFN receptors (Figure 3B). In contrast, 230 
PR8 but not DI-244 induced expression of IFN  and IFN  (Figure 3B). Despite the 231 
differential upregulation of IFNs by PR8 and DI-244 both induced the robust expression of 232 





efficient than that observed for DI-244 (Figure 3B). Moreover, no ISG induction was 234 
observed in PR8 or DIP treated A549 STAT1-/- cells, with the exception of ISG15 and 235 
RSAD2 (Viperin), the expression of which was induced by PR8 but not IAV. Finally, results 236 
with A549 wt cells were confirmed by qRT-PCR analyses. Induction of IFN  and IFN  by 237 
DI-244 was at least 100-fold less efficient as compared to PR8 while differences in ISG 238 
induction were frequently less than 10-fold (Figure 3C). In sum, these results suggest that DI-239 
244 inhibits viral infection by the IFN-independent, STAT1-dependent induction of ISG 240 
expression.  241 
 242 
DISCUSSION 243 
DI RNAs arise in IAV infected cell cultures, eggs, animals and patients (Bean et al., 1985; 244 
Chambers and Webster, 1987; Dimmock and Easton, 2014, 2015; Dimmock et al., 2008; 245 
Saira et al., 2013; Von Magnus, 1954). They inhibit IAV infection and might modulate IAV 246 
intra- and interpatient spread and pathogenesis. However, the mechanism underlying DI RNA 247 
antiviral activity and the determinants controlling whether a defective viral genomic RNA is 248 
also interfering are incompletely understood. Here, we show that any central deletion in 249 
segments 1, 2 and 3 of IAV is sufficient to convert these RNAs into DI RNAs and that 250 
inhibitory activity of the respective DI RNAs extends to all tested IAV genomic RNAs. 251 
Moreover, we provide evidence that the contribution of replication interference to DIP 252 
antiviral activity in cell culture is minor as compared to induction of the IFN system.  253 
 IAV and influenza B virus DI RNAs usually contain deletions relative to the genomic 254 
RNAs they arose from (Dimmock and Easton, 2014, 2015), although an exception has 255 
recently been reported (Kupke et al., 2019). Moreover, DI RNAs derived from IAV segments 256 
1-3, which encode the subunits of the viral polymerase, arise more frequently than those 257 
derived from other segments (Davis et al., 1980; Davis and Nayak, 1979; Dimmock and 258 





and were thus in the focus of the present study. The almost universal presence of a deletion in 260 
DI RNAs suggests that their shorter length might allow them to out-compete their parental 261 
RNAs for resources required for RNA replication. Although this hypothesis is frequently 262 
posited (Dimmock and Easton, 2014, 2015), direct experimental proof is largely lacking. Here 263 
we provide this proof by demonstrating that deleting any internal sequence from segments 1, 264 
2 and 3 is sufficient to generate a DI RNA. Furthermore, we demonstrate that the inhibitory 265 
activity of these DI RNAs is determined by their length, at least in the absence of an IFN 266 
response, and extends to all target segments tested. The latter observation fits with the finding 267 
that DI-244 interferes with replication of several genomic RNAs in IAV infected cells (Meng 268 
et al., 2017). In sum, deleting the sequences between the conserved 5  and 3  ends of any IAV 269 
RNA, which are required for transcription and translation, should generate potent DI RNAs. 270 
In some cases, the truncated open reading frame encoded by such DI RNAs might contribute 271 
to antiviral activity (Boergeling et al., 2015) but this was not observed for DI-244, in keeping 272 
with previous results (Meng et al., 2017). 273 
 Type I IFN triggers the expression of about 400 genes, many of which encode proteins 274 
with antiviral activity, including MX1 (Schoggins et al., 2011). The present study shows that 275 
when conditions are chosen that allow DIPs to activate the IFN system, DIPs are potent 276 
inducers of ISG expression and the contribution of replication interference to DIP antiviral 277 
activity is minor. Notably, RNAseq analysis revealed that IAV but not DIPs robustly induced 278 
type I and type III IFN expression although both triggered ISG expression in a STAT1-279 
dependent fashion. A potential explanation for this discrepancy is that DIPs induced IFN 280 
expression at levels too low to be detected by RNAseq but still sufficient to induce ISGs. 281 
Indeed, qRT-PCR analysis revealed modest upregulation of type I and III IFN upon DIP 282 
treatment. Alternatively, DIPs may induce ISGs via an unknown IFN-independent, STAT1-283 
dependent pathway. Interestingly, Wang and colleagues also reported that DIPs induce robust 284 





underlying reasons. Moreover, it is unclear how undiluted DIPs exerted anti-IAV but not anti-286 
VSV activity in STAT1-/- cells without inducing ISGs or other cellular genes. Collectively, 287 
our results underline previous findings that DIPs are potent IFN inducers (Baum et al., 2010; 288 
Frensing et al., 2014; Ngunjiri et al., 2013; Ngunjiri et al., 2012; Perez-Cidoncha et al., 2014) 289 
and show that DIP antiviral activity due to IFN induction outweighs that due to replication 290 
interference. 291 
 What are the major implications of our findings for DIP development as antivirals and 292 
for elucidating the role of naturally occurring DIPs in IAV infection? First, it is essential that 293 
antiviral activity of DIPs is examined in IFN competent animal models which express ISGs 294 
with potent anti-IAV activity, particularly MX1. Second, antiviral activity due to replication 295 
interference can be attained only if DIPs are added in 100 to 1,000-fold excess relative to 296 
virus (Bdeir et al., 2019) and it remains to be examined whether the strong IFN induction 297 
under those conditions exerts unwanted toxic effects in animals and humans. Third, DIP 298 
treatment should be more effective in the prophylactic as compared to the therapeutic setting, 299 
since only in the former DIP-induced IFN can fully contribute to antiviral activity. Fourth, 300 
design of DI RNA and analysis of DI RNAs emerging in patients should focus on the smallest 301 
RNAs, since they can be expected to exert the highest antiviral activity. 302 
 303 












MATERIAL AND METHODS 312 
 313 
Plasmids and oligonucleotides 314 
Plasmids for rescue of A/PR/8/34, pHW191-pHW198, and A/WSN/33, pHW181-pHW188, 315 
were previously described (Hoffmann et al., 2002). Plasmids encoding DI RNAs were 316 
generated by splice overlap PCR, joining 5  and 3 -end sequences of desired length, following 317 
a strategy previously described for DI-244 (Bdeir et al., 2019). A multiple cloning site (mcs) 318 
for later insertion of a reporter gene was included in the respective oligonucleotide sequences 319 
(Table S2). The PCR products were cloned into pHW2000-GGAarI by golden gate cloning 320 
(Eckert et al., 2014). Start codons in DI-244 were mutated using splice overlap PCR primer 321 
pairs mutIAV-seg1-ATG-for (5 - TCAATTATATTCAATTTGGAAAGAATAAAAG -322 
3 )/mutIAV-seg1-ATG-rev (5 - CTTTTATTCTTTCCAAATTGAATATAATTGA-3 ) and 323 
DImut2+3ATG-for (5  ACTACGAAATCTAATCTCGCAGTCTCGCACCCGCGAGATAC 324 
TCACAAAAACCACCGTGGACCATATCGCCATAATCAAGAAG-3 )/DImut2+3ATG-325 
rev (5 -CTTCTTGATTATGGCGATATGGTCCACGGTGGTTTTTGTGAGTATCTCGCG 326 
GGTGCGAGACTGCGAGATTAGATTTCGTAGT-3 ). PCR constructs were cloned into 327 
pHW2000-GGAarI as described above. 328 
For expression of the truncated PB2 ORF from DI-244, the ORF was amplified from 329 
pHW2000GG-DI244-rep using primers PB2-QCXIP-5N (5 - CCGCGGCCGCACCATGGA 330 
AAGAATAAAAGAACTAC-3 )/PB2-3XBgl (5 -GGAGATCTCGAGCTAATTGATGGCC 331 
ATCCGAAT-3 ) digested with NotI/XhoI and cloned into NotI/SalI digested pCAGGS-mcs 332 
bearing an altered multiple cloning site (XhoI-SacI-Asp718I-NotI-EcoRV-ClaI-EcoRI-SmaI-333 
SalI-SphI-NheI-BglII). 334 
For generation of empty vector p19polI-GGAarI the insert was amplified from pHW2000-335 
GGAarI by splice overlap PCR using primers HW2-GG-5Bgl, CCdelE-rev (5 -336 





CTGATGAATGCTCATCCGGAGTTTCGTATGGCAATGAAAGACG-3 )/ rRNA-Pr(GG)-338 
3Eco (5 -GCGAATTCTATAGAATAGGGCCAGGTC-3 ) and cut with BglII and EcoRI for 339 
insertion into BamHI and EcoRI digested p19luc (Winkler et al., 1994). 340 
Reporter plasmids for mini-replicon assay have been described (pPolI-Luc 341 
(vRNA/FLUAV/NS1 Seg8-NCR) (Zimmermann et al., 2011) or were newly generated. First, 342 
the reporter with segment 8 ends was amplified with primers fluA AarI-NS-1 and fluA AarI-343 
NS-890R (Table S3) and inserted into vector p19polI-GGAarI by Golden Gate cloning. To 344 
generate reporters with ends derived from other segments of IAV, the luciferase reporter gene 345 
was amplified with primers encoding the respective untranslated regions (Table S3) and 346 
cloned into vector p19polI-GGAarI as described before. All PCR amplified sequences were 347 
confirmed by automated sequence analysis. 348 
 349 
Cells and viruses 350 
293T, A549 wt and A549 STAT1-/- cells were maintained in Dulbecco s Modified Eagle 351 
Medium (DMEM; Gibco) containing 10% fetal bovine serum (FBS, Gibco) and penicillin 352 
(Pen, 100 IU/mL) and streptomycin (Strep, 100 µg/ml). BHK-21 cells were cultivated in 353 
Dulbecco s modified Eagle medium (DMEM, Pan Biotech) supplemented with 5% fetal 354 
bovine serum and pen/strep. 293T cell lines stably expressing codon optimized PB2 (293T-355 
PB2opt) were cultured in the presence of 1 µg/ml puromycin.  Madin-Darby canine kidney 356 
cells (MDCK) were cultured in Glasgow s Modified Eagle Medium (GMEM; Gibco) 357 
supplemented with 10% fetal bovine serum (FBS, Gibco) and pen/strep. MDCK cells stably 358 
expressing PB2opt were maintained in the presence of 1.5 µg/ml puromycin. For generation 359 
of A549 STAT1-/- cells, A549 wt cells were transduced with a commercially available 360 
lentivirus expressing Cas9 (Addgene, plasmid 52961), puromycin resistance, and a guide 361 
RNA targeting human STAT1 (TTCAAGACCAGCGGCCTCTGAGG).  Transduced cells 362 





single cells and expanded. Clonal populations were then lysed and whole cell extract was 364 
examined for STAT1 expression by Western blot.  These efforts identified a single clone that 365 
demonstrated a complete loss of STAT1 expression, which we refer herein as STAT1-/- cells. 366 
All cells lines were regularly tested for mycoplasma contamination.   367 
 A/PR/8/34 (H1N1) and A/WSN/33 (H1N1) (Hoffmann et al., 2002) were produced in 368 
embryonated chicken eggs as described previously (Zmora et al., 2017) while A/WSN/33 369 
adapted to growth in A549 cells was obtained from the strain repository of the IVM Münster 370 
and was amplified in A549 cells by continuous passaging. IAV titers were determined using 371 
focus formation assay as described (Eckert et al., 2014; Winkler et al., 2012). Replication-372 
competent vesicular stomatitis virus (VSV) expressing eGFP and either wildtype VSV matrix 373 
protein (VSV*) or a matrix protein variant harboring four amino acid substitutions associated 374 
with increased induction of type-I interferon response (VSV*MQ) have been described 375 
elsewhere (Hoffmann et al., 2010) and were amplified using BHK-21.  Further, a VSV 376 
glycoprotein trans-complemented, single-cycle VSV replicon that lacks the genetic 377 
information for VSV-G but instead codes for eGFP and firefly luciferase genes (VSV* G-378 
FLuc) (Berger Rentsch and Zimmer, 2011) was employed and propagated on BHK-G43 cells 379 
(Hanika et al., 2005). All VSV variants were titrated on BHK-21 cells and eGFP-positive foci 380 
(replication-competent VSV) or eGFP-positive single cells (single-cycle VSV) were counted. 381 
 382 
Mini-replicon assay 383 
The mini-replicon assay was performed as described (Zimmermann et al., 2011). In brief, 384 
293T cells seeded in 12-well plates at a cell density of 2 x 105 cells per well were 385 
cotransfected with plasmids encoding PB1 (10 ng), PB2 (10 ng), NP (100 ng), reporter 386 
segment encoding firefly luciferase (50 ng) and plasmid encoding a DI RNA or empty 387 
plasmid (amounts indicated in figures or figure legends). Cells were washed at 6-8 h and 388 





using a commercial kit (PJK) and the Plate Chameleon V reader (Hidex) jointly with 390 
Microwin 2000 software.  391 
 392 
Production of DIPs 393 
A coculture of 1.4 ×106 293T cells and 0.4 ×106 MDCK cells stably expressing PB2opt and 394 
seeded in T-25 flask was cotransfected with plasmids encoding IAV genomic segments 2-8 of 395 
either PR8 or WSN origin and a plasmid encoding a segment 1-derived DI-RNA. After 396 
overnight incubation, cells were washed once with PBS and, for production of A/PR/8/34-397 
derived DIPs, DMEM infection medium (0.2% MACS BSA, 1% pen/strep) supplemented 398 
with TPCK trypsin (0.5 µg/ml) was added. For production of A/WSN/33-derived DIPs, 399 
DMEM growth medium (2% FCS, 1% pen/strep) was added. As a negative control, parental 400 
MDCK and 293T cells were transfected. Supernatants containing A/PR/8/34-derived DIPs 401 
were harvested at 4, 6, 8 and 10 days post transfection while supernatants containing 402 
A/WSN/33-derived DIPs were harvested at 3, 5, 7 and 9 days post transfection. Supernatants 403 
were cleared from debris by centrifugation, aliquoted and stored at -80 °C for further use. For 404 
some experiments, DIPs were further amplified in MDCK-PB2opt cells. For this, a total of 3 405 
×106 cells were seeded in T-75 flasks and infected at an MOI of 0.01 or lower. Upon detection 406 
of CPE, supernatants were cleared from debris by centrifugation and sterile-filtration (0.45 407 
µm filter), aliquoted and stored at -80 °C for further use. Integrity of selected DIP 408 
preparations was controlled with segments specific PCR. Infectious titers of supernatants 409 
were determined by focus formation assay using MDCK-PB2opt cells as targets, as described 410 
(Bdeir et al., 2019; Eckert et al., 2014; Winkler et al., 2012). 411 
 412 
Analysis of antiviral activity of DIPs 413 
For testing the antiviral activity of DIPs in MDCK cells in the presence of trypsin, cells were 414 





dilutions) and IAV (A/PR/8/34, MOI 0.001) for 1 h in Glasgow's MEM (GMEM) infection 416 
medium containing trypsin (0.5 µg/ml). Alternatively, DIPs were added 24 h prior to the 417 
virus. For analysis of DIP antiviral activity in MDCK cells, A549 wt and A549 STAT1-/- cells 418 
in the absence of trypsin, cells were again seeded at 10,000 cells/well in 96-well plates and 419 
either coinfected with DIP (MOI 5 or 10, and 10-fold dilutions) and IAV (A/WSN/33, MOI 420 
0.1) in DMEM medium without trypsin or DIPs added 24 h prior to the virus. After 1 h, cells 421 
coexposed to DIPs and virus were washed and culture medium with or without trypsin was 422 
added. Supernatants were harvested after 72 h (MDCK) and 96 h (A549 wt and A549 STAT1-423 
/-). Viral titers in culture supernatants were quantified using focus formation assay and MDCK 424 
cells, as described (Eckert et al., 2014; Winkler et al., 2012). 425 
 426 
Quantitative RT-PCR analysis  427 
In order to investigate modulation of MX1 mRNA expression by IAV, DIPs and IFN, a 428 
quantitative RT-PCR assay was performed. For this, A549 cells were seeded at a cell density 429 
of 2 ×105 cells/well in 12-well plates and inoculated with IAV (MOI 1), DIPs (MOI 1) or pan-430 
IFN  (100 U/ml, PBL Assay Science) using DMEM infection medium for 1 h (DMEM 431 
infection medium without trypsin was added to cells exposed to IFN ). Then cells were 432 
washed once with PBS and cultured in DMEM infection medium without trypsin for 24 h. To 433 
assess the effect of trypsin on MX1 induction by IFN , cells were incubated for 24 h with 434 
IFN  in the presence of 0, 0.5, 0.05 and 0.005 µg/ml trypsin. At 24 h post treatment, total 435 
cellular RNA was extracted using the RNeasy Mini kit (Qiagen) following the manufacturer s 436 
instructions. After determining the RNA content, 1 µg RNA was used as template for cDNA 437 
synthesis employing the SuperScript III First-Strand Synthesis System (ThermoFisher 438 
Scientific), following the protocol for random hexamers. Subsequently, 1 µl of cDNA (total 439 
volume after cDNA synthesis: 20 µl) was analyzed by quantitative PCR on a Rotorgene Q 440 





analyzed in triplicates for transcript levels - given as cycle threshold (Ct) values - of ß-actin 442 
(ACTB, internal transcript control) and myxovirus resistance protein 1 (MX1, indicator for 443 
IFN induction, target transcript) with primers previously reported by Biesold and colleagues 444 
(Biesold et al., 2011). In order to analyze the gene expression, the 2- Ct method was used 445 
(Livak and Schmittgen, 2001).  446 
 447 
Vesicular Stomatitis Virus Replicon-Based Bioassay 448 
To analyze the relative contribution of IFN induction to antiviral activity, a VSV replicon-449 
based bioassay was performed. This assay is based on the principle that inoculation of 450 
effector cells with virus or DIPs leads to the induction of the innate immune system, resulting 451 
in the release of type-I IFN into the culture supernatant. These supernatants are then used to 452 
inoculate sentinel cells. Here, the type-I IFN will bind to the IFN /  receptors and trigger a 453 
signal cascade leading to the induction of an antiviral state. Subsequent inoculation of the 454 
sentinel cells with a highly IFN-sensitive VSV replicon containing a luciferase reporter will 455 
yield luciferase activities that inversely correlate with the extent of the induced antiviral state.  456 
A549 and A549 STAT1-/- cells (= effector cells) were seeded in 12-well plate (200,000 457 
cells/well) and inoculated with IAV, VSV*, VSV*-MQ or DIPs (all at MOI of 1) using 458 
DMEM infection medium containing trypsin for 1h. The cells were washed once with PBS 459 
and cultured in DMEM infection medium without trypsin (used for all further steps) for 16-18 460 
hours. Next, supernatant was harvested, and infectious virus was inactivated by addition of 461 
0.1 M HCl and heating the samples for 30 mins to 56 °C. After the samples cooled down to 462 
room temperature, alkaline treatment was performed using 0.1 M NaOH to neutralize the 463 
acidic pH. Subsequently, the two-fold serial dilutions of the samples were prepared. In 464 
addition, medium containing two-fold serial dilutions of recombinant pan IFN  (starting at a 465 
concentration of 400 U/ml) were treated in the same fashion. These samples served as 466 





supernatants (given as relative IFN  units per ml). The diluted supernatants and IFN  468 
reference samples were added in quadruplicates to a confluent layer of A549 cells grown in 469 
96-well plates (= sentinel cells) and incubated for 18-24 h. Thereafter, the cells were 470 
inoculated with VSV* G-FLuc reporter virus (MOI of 3) and further incubated for 6 h. Then, 471 
the medium was aspirated and 50 µl/well of 1x luciferase lysis buffer was added. Following 472 
an incubation period of 30 min, the lysates were transferred into white, opaque-walled 96-473 
well plates and firefly luciferase activity was measured as described above for the mini-474 
replicon assay. For normalization, luciferase activity was set as 100 % for cells that received 475 
regular culture medium instead of diluted culture supernatant/IFN  prior to inoculation with 476 
VSV* G-FLuc. Using the normalized luciferase values of cells treated with the IFN  477 
reference samples and a non-linear regression model we then calculated the relative IFN  478 
content (given as units per ml) for the effector cell supernatants.  479 
 480 
RNA-seq analysis 481 
For analysis of IAV and DIP mediated modulation of cellular gene expression, A549 wt and 482 
A549 STAT1-/- cells were exposed to A/PR/8/34, DI-244 or control supernatants at a MOI of 483 
1. At 24 h post treatment, total cellular RNA was extracted using the RNeasy Mini kit 484 
(Qiagen) following the manufacturer s instructions and subsequently sent for RNAseq 485 
analysis at the Integrative Genomics Core Unit (NIG), Department of Human Genetics, 486 
University Medical Center Göttingen.  487 
RNA-seq libraries were performed using the non-stranded mRNA Kit (Illumina). Quality and 488 
integrity of RNA was assessed with the Fragment Analyzer using the standard sensitivity 489 
RNA Analysis Kit (Advanced Analytical). All samples selected for sequencing exhibited an 490 
RNA integrity number of >8. After library generation, we used the QuantiFluor dsDNA 491 
System (Promega) for accurate quantitation of cDNA libraries. The size of final cDNA 492 





exhibiting a sizing of 300 bp in average. Libraries were pooled and sequenced on an Illumina 494 
HiSeq 4000 (Illumina) generating 50 bp single-end reads (28-35 Mio reads/sample). The raw 495 
read & quality check were done by transforming sequence images with the BaseCaller 496 
software (Illumina) to BCL files, which were demultiplexed to fastq files with bcl2fastq 497 
v2.20. The sequencing quality was asserted using FastQC 498 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  499 
For subsequent data analysis, ISGs with anti-IAV activity were selected based on work by 500 
Schoggins and colleagues (Schoggins et al., 2011). ISG expression in IAV- or DIP-treated 501 
cells is shown relative to expression of the same ISGs in control-treated cells.  502 
 503 
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 643 
FIGURE LEGENDS 644 
 645 
Figure 1. Antiviral activity of DI RNAs inversely correlates with DI RNA length in the 646 
presence of trypsin 647 
 (A) DI-244 inhibits genome replication in the mini-replicon assay. 293T cells were 648 
transfected with plasmids encoding the viral polymerase proteins, NP, a segment 8-based 649 
luciferase reporter (mini-replicon system) and either empty plasmid or plasmid for expression 650 
of DI-244 mRNA (10 and 300 ng) and vRNA. Removing the plasmid encoding PB2 from the 651 
transfection mix served as negative control. Cotransfection of all support plasmids and empty 652 
plasmid instead of DI-244 encoding plasmid served as positive control. The average of five 653 
independent experiments is shown, for which the positive control was set as 100%. Error bars 654 
indicate standard error of the mean (SEM).  655 
(B) The truncated open reading frame of DI-244 does not contribute to inhibition of genome 656 
replication in the mini-replicon assay. The experiment was carried out as described for panel 657 
A but the cells were cotransfected with a plasmid for expression of DI-244 mRNA and vRNA 658 
with or without the first three ATGs of the PB2 ORF being intact (DI-244, DI-244 mut ATG), 659 
a plasmid for expression of DI-244 mRNA (DI-244 ORF) or empty plasmid pCAGGS. The 660 
average of three independent experiments is shown, for which the positive control was set as 661 





(C) The inhibitory activity of segment 1-derived DI RNAs in the mini-replicon assays is 663 
inversely correlated with DI RNA length. The experiment was carried out as described for 664 
panel A but 300 ng of plasmids harboring the indicated segment 1-derived DI RNAs were 665 
cotransfected. The DI RNAs tested were numbered as shown in table S1. The average of five 666 
independent experiments is shown, for which the positive control was set as 100%. Error bars 667 
indicate SEM.  668 
(D) The inhibitory activity of segment 2- and 3-derived DI RNAs in the mini-replicon assays 669 
is inversely correlated with DI RNA length. The experiment was conducted as described for 670 
panel A but 300 ng of plasmids harboring the indicated segment 2 and 3-derived DI-RNAs 671 
were cotransfected. The DI RNAs tested were numbered as shown in table S1. The average of 672 
three independent experiments is shown, for which the positive control was set as 100%. 673 
Error bars indicate SEM.  674 
(E) The inhibitory activity of DI RNAs in the mini-replicon assays is independent from the 675 
origin of the reporter segment. The experiment was carried out as described for panel A but 676 
the indicated reporter segments and segment 1, 2 and 3-derived DI RNAs were used. The 677 
results of a single representative experiment are shown and were confirmed in an independent 678 
experiment. Error bars indicate standard deviation (SD).  679 
(F) Antiviral activity of segment 1-derived DIPs is inversely correlated with DI RNA lengths 680 
in the presence of trypsin. MDCK cells were coinfected with the indicated DIPs (MOI 1) and 681 
A/PR/8/34 (MOI 0.001) in the presence of trypsin, washed, and cultured in medium with 682 
trypsin. DIP-negative supernatants served as controls. At 72 h post infection, viral titers in 683 
culture supernatants were determined by focus formation assay. The average of four 684 
independent experiments is shown; error bars indicate SEM. In panels A-D statistical 685 
significance of differences between values measured for cells cotransfected with support 686 
plasmids and either empty plasmid (+ control) or DI RNA encoding plasmid was determined 687 





D). In panel F statistical significance of differences between values measured for cells with 689 
virus and DIPs at reciprocal DIP dilution was determined using one-way ANOVA with 690 
Dunnett´s posttest. *, p  0.05; **, p  0.01; ***, p  0.001 691 
 692 
Figure 2. Induction of the IFN system is a major contributor to DIP antiviral activity 693 
(A) Trypsin inactivates IFN . A549 wt cells were exposed to recombinant IFN  (100 U/ml) 694 
in the presence and absence of serially diluted trypsin (T). Undiluted trypsin (IFN  + T) was 695 
added at a concentration of 0.5 µg/ml. After 24 h, cells were harvested, RNA isolated and 696 
MX1 expression analyzed by quantitative RT-PCR. MX1 transcripts levels were normalized 697 
against ß-actin transcript levels. The average of three independent experiments is shown. 698 
Error bars indicate SEM.  699 
(B) Pre-exposure of target cells to DIPs boosts DIP antiviral activity independent of trypsin. 700 
Left panel, - Trypsin condition: MDCK cells were either coinfected with DI-244 (MOI 10) 701 
and A/WSN/33 (MOI 0.1) in the absence of trypsin or DI-244 was added to cells at 24 h 702 
before virus. Cells were washed 1 h after addition of virus and maintained in growth medium. 703 
At 72 h post infection, viral titers in culture supernatants were determined by focus formation 704 
assay. Right panel, + trypsin condition: The experiment was carried out as described for the 705 
left panel, but A/WSN/33-derived DIPs (MOI 1) and A/WSN/33 (MOI 0.001) were used and 706 
maintained in infection medium supplemented with trypsin. The average of three independent 707 
experiments is shown in both panels; error bars indicate SEM.  708 
(C) STAT1 is required MX1 induction by IAV and DIP. A549 cells and A549 STAT1-/- cells 709 
were exposed to IFN  (100 U/ml), A/PR/8/34 or DI-244 (all MOI 1, in the presence of 710 
trypsin) for 1 h, washed, incubated for 24 h in the absence of trypsin and MX1 mRNA 711 
expression quantified using qRT-PCR. The average of five independent experiments is 712 





(D) Anti-IAV activity of DI-244 is partially and anti-VSV activity of DIP is fully dependent 714 
on STAT1. Antiviral activity of DI-244 was analyzed as described for the left panel of figure 715 
2B but A549 wt and A549 STAT1-/- cells were used. At 96 h post infection, viral titers in 716 
culture supernatants were determined by focus formation assay. The average of six 717 
(A/WSN/33) and three independent experiments (VSV) is shown. Error bars indicate SEM.  718 
(E) DI RNA length does not modulate DIP antiviral activity in the context of a functional IFN 719 
system. Antiviral activity of the indicated DIPs was analyzed as described for panel D adding 720 
DIPs 24 h before virus. The average of five independent experiments is shown. Error bars 721 
indicate SEM. 722 
In panels B and D statistical significance of differences between values measured for cells 723 
inoculated with DIPs at 24 h before IAV infection and cells to which IAV and DIPs were 724 
added at the same time was determined using two-way ANOVA with Sidak´s posttest. In 725 
panel E statistical significance of differences between values measured for cells with virus 726 
and DIPs at reciprocal DIP dilution was determined using one-way ANOVA with Dunnett´s 727 
posttest. *, p  0.05; **, p  0.01; ***, p  0.001 728 
 729 
Figure 3. DI-244 robustly induces ISG but not IFN expression 730 
 (A) DI-244 does not induce IFN expression as determined in a VSV-replicon-based bioassay. 731 
A549 and A549 STAT1-/- cells were exposed to IAV, VSV or DI-244 and supernatants 732 
collected, heat inactivated, acid treated and added onto A549 cells followed by infection with 733 
VSV. For calibration, A549 cells were incubated with recombinant IFN , VSV infected and 734 
infection efficiency was quantified. The average of three independent experiments is shown. 735 
Error bars indicate SEM. 736 
(B) DI-244 induces robust ISG but not IFN expression as determined by RNAseq. A549 cells 737 
(top panel) and A549 STAT1-/- cells (bottom panel) were incubated with IAV (A/PR/8/34), 738 





RNAseq analysis. Expression of selected ISGs is shown. The average of two independent 740 
experiments (A549) and three experiments (A549 STAT1-/-) is presented. Error bars indicate 741 
SEM. 742 
(C) DI-244 induces robust ISG but not IFN expression as determined by qRT-PCR analysis. 743 
The A549 wt cells described in panel B were subjected to qRT-PCR analysis of ISG 744 
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Segment 1-derived DI-RNAs 
 
Nr. Name Total (b) 5  e d (b) 3  e d (b) 
1 DI-244 421 151 244 
2 DI-346 623 252 346 
3 DI-448 829 354 448 
4 DI-550 1032 456 550 
5 DI-662 1236 558 652 
6 DI-754 1440 660  754 
7 DI-856 1645 762 856 
8 DI-958 1849 864 958 
9 DI-1060 2051 966 1060 
10 DI-1162 2256 1068 1162 
 
Segment 2-derived DI-RNAs 
 
Nr. Name Total (b) 5  e d (b) 3  e d (b) 
1 DI-156 334 151 156 
2 DI-258 537 252 258 
3 DI-360 741 354 360 
4 DI-462 945 456 462 
5 DI-666 1353 660 666 
6 DI-870 1761 864 870 
7 DI-1074 2169 1068 1074 
 
Segment 3-derived DI-RNAs 
 
Nr. Name Total (b) 5  e d (b) 3  e d (b) 
1 DI-178 346 141 178 
2 DI-280 550 243 280 
3 DI-382 754 345 382 
4 DI-484 958 447 484 
5 DI-688 1366 651 688 
6 DI-892 1774 855 892 
7 DI-1096 2182 1059 1096 
All constructs contain an mcs  
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6.1 First Manuscript - A system for production of defective interfering particles in the 
absence of infectious influenza A virus 
DIPs appear naturally during influenza virus infections at high MOI and were first observed in 
embryonated chicken eggs while performing serial passaging of influenza A virus (Magnus 
1954). Subsequently, it was discovered that DIPs can protect cell cultures and animals from 
wt influenza virus infection, indicating that they could be developed as antiviral agents 
(Dimmock et al. 2008; Easton et al. 2011). However, their production was dependent on the 
presence of wt virus which needed to be UV-inactivated. To tackle this limitation, a cell line-
based system for production of DIPs in the absence of wt virus was established. This 
lessened safety concerns and resulted in substantial homogeneity of DIP preparation and 
thus could facilitate DIP use in humans.  
To produce DI-244 particles in the absence of wt virus, 293T and MDCK cell lines stably 
expressing the IAV polymerase subunit PB2 were generated using retroviral technology. This 
approach was chosen since the PB2 ORF was inactivated in DI-244 (which was derived from 
IAV genomic segment 1) and providing the PB2 protein in trans should allow amplification of 
DIPs harbouring wt genomic segments 2-8 jointly with DI-244. 293T cells were chosen for DIP 
production because of high transfectability while MDCK cells were used because of high 
permissiveness to IAV infection. The DI-244 production in these 293T/MDCK cocultures 
yielded about 106 DI-244 infectious particles/ml when quantified using MDCK PB2opt cells 
for focus formation assay – the first time that DIP infectivity has been ever quantified. A 
similar study also generated about 107 DI-244 PFU/ml using AX4 cells stably expressing PB2 
protein, but they mutated all start codons of DI-244 RNA to prevent unexpected expression 
of unrelated proteins (Yamagata et al. 2019). Previous studies reported about 10 to 100-fold 
higher yields of DI-244 in embryonated chicken eggs, amplified in cell-culture, and 
bioreactors but these production systems depended on use of wt virus and reported viral 
genome copies/ml and not infectious unit/ml (Dimmock et al. 2008; Frensing et al. 2013; 
Wasik et al. 2018). Considering that only a fraction of particles containing RNA will also be 
infectious and interfering, the particle yields obtained here can be considered robust. 
Moreover, this study was the first to report DIP production in the absence of wt IAV and thus 
did not encompass UV irradiation to inactivate wt IAV. UV inactivation relies on the fact that 





inactivated by UV. Moreover, any inactivating mutation in other segments will abrogate 
infectivity of wt IAV but not DIPs, since the latter only need to deliver their DI-RNA into wt 
IAV coinfected cells to ensure their amplification. Considering that UV inactivation can be 
inefficient for large scale production of DIPs and yields variable results, the newly 
established DIP production system constitutes a significant advance. 
The 293T and MDCK cells used for DI-244 production were equipped with expression 
cassettes for codon optimized PB2 to ensure efficient expression and to avoid potential 
recombination events with DI-244, which would result in the production of wt IAV. The use 
of codon optimized PB2 increased PB2 expression in MDCK cells and improved DIP yields 
about 100-fold. Additionally, no evidence of recombination events between DI-244 RNA and 
PB2 RNA was neither observed with confocal microscopy or immunofluorescence, nor 
quantified through focus formation assay or RT-PCR analysis. For visual examination of DI-
244 production and spread, DI-244-mScarlet was generated as it encodes a red fluorescent 
protein. The robust production of DI-244-mScarlet in PB2opt expressing cells raised the 
question of whether the particles exerted antiviral activity. MDCK cells co-infected with PR8 
and DI-244-mScarlet demonstrated that DI-244 displayed robust and concentration-
dependent antiviral activity. Moreover, antiviral activity was also observed with a H3N2 IAV, 
A/Panama/2007/99, but not with VSV. The inhibition of diverse IAV by DI-244 was expected 
from published studies (Dimmock et al. 2008) and reflected replication interference, i.e. the 
DI-RNA outcompetes wt RNAs for viral and cellular genome replication requirements 
(Dimmock and Easton 2014, 2015). The lack of VSV inhibition is noteworthy since DIPs are 
known to inhibit heterologous viruses (Easton et al. 2011; Scott et al. 2011a) by eliciting an 
IFN response (Scott et al. 2011a, 2011b) and not by genome competition (Scott et al. 2011c; 
Easton et al. 2011). The IFN response was likely suppressed in the cell culture systems used 
in the present study. This is the effect of trypsin that was used to ensure robust IAV and DIP 
spread but inactivates type I IFN (Seitz et al. 2012). This means that antiviral activity incurred 
by DIPs is largely due to replication interference in the case of IAV but not VSV which lacks 
genome competition. Robust antiviral activity of DIPs was observed when these particles 
were used at a 100 or 1000-fold excess as compared to wt IAV. This DIP/wt virus ratio is 
similar to that used for previously published animal studies (IAV/DIP ratio of 1:3400 





What are the implications of the above discussed findings for DIP use in humans? A DIP to 
virus ratio of 1000:1 was required for robust DIP antiviral activity in cell culture. It could be 
speculated that a lower ratio will suffice in humans, as DIPs can stimulate IFN responses in 
vivo although those responses were probably not stimulated in the cell culture systems used 
to determine DIP antiviral activity, as discussed below. Considering that DIPs reside for a 
long time in the respiratory tract of mice, and studies with DIP-treated animals reported one 
week protection after treatment (Dimmock et al. 2008; Dimmock and Easton 2015), DIP 
stability in the respiratory tract of humans should not be considered as an impediment to 
provide protection against influenza virus, which needs to be further investigated. Finally, it 
could be stated that although DIPs can reassort with wt IAV in coinfected cells, such a 
reassortment is unlikely to raise safety concerns since, first, the largely apathogenic PR8 was 
used for DIP production, and second, recombination of wt IAV with PR8 would not increase 
virulence of reassortant virus as compared to the wt virus. 
The results discussed above were obtained with DI-244-mScarlet particles. Pure DI-244 wt 
particles were expected to be produced under same conditions. Unexpectedly, this was not 
the case and a potential explanation for this issue was provided by results obtained in the 
mini-replicon assay (discussed in second manuscript). DI-244 RNA suppressed replication of 
IAV segments, and the inhibitory activity was found to be length dependent. This indicated 
that DI-244 wt might have higher antiviral activity than DI-244-mScarlet and that expression 
of high amounts of DI-244 wt might auto-inhibit segment amplification and particle 
production. Further analysis of the results showed that the efficiency of particle production 
of DI-244 wt in PB2opt cells inversely correlated with the amount of DI-244 wt plasmid 
transfected.  
In summary, this study demonstrated that cell lines expressing PB2opt allow production of 
DI-244 particles in the absence of wt virus. The particles exerted anti-IAV activity and their 
infectivity could be determined by focus formation assay. No recombination events between 
DI-244 RNA and PB2 full-length RNA were observed by immunofluorescence microscopy, 
focus forming assay and RT-PCR analysis, indicating that DIPs produced in the system are 
homogenous and safe. Thus, a DIP production system not relying on wt virus was reported 





6.2 Second Manuscript - Interferon induction and not replication interference is the 
major determinant of anti-influenza virus activity of defective interfering particles  
DI-RNAs are found in IAV infected eggs (Magnus 1954), cell cultures (Dimmock et al. 2008; 
Frensing et al. 2013), animals (Bean et al. 1985; Barrett and Dimmock 1986; Chambers and 
Webster 1987; Dimmock and Easton 2014, 2015), and patients (Saira et al. 2013; Vasilijevic 
et al. 2017). They interfere with the replication of the wt IAVs from which they originated 
but also inhibit unrelated viruses (Easton et al. 2011; Scott et al. 2011a). Replication 
interference and IFN induction are important mechanisms by which DIPs inhibit IAV (Vignuzzi 
and López 2019). DIPs suppress influenza virus infection by interfering with genome 
replication (a process termed replication interference) and by stimulating immune response 
(IFN induction) (Dimmock and Easton 2014, 2015; Scott et al. 2011a, 2011b). However, the 
relative contribution of replication interference and IFN induction to DIP antiviral as well as 
the mechanism underlying IFN induction are incompletely understood. The present study 
provides evidence that the contribution of replication interference to DIP antiviral activity is 
minor as compared to IFN induction. Moreover, the study reveals that DIP-dependent 
activation of the IFN system encompasses induction of ISG but not IFN expression. 
The concept behind replication interference posits that DI-RNA outcompete their wt 
counterparts for viral and cellular resources required for replication because they are 
smaller and thus replicate faster (Li and Pattnaik 1997; Calain and Roux 1995). On the other 
hand, the concept has not been systematically investigated. To close this gap, variants of 
genomic segments 1, 2, and 3 with nested deletions were generated. A mini-replicon assay, 
which measures genome replication and mRNA expression, showed that DI-RNA length 
inversely correlated with inhibitory activity. Besides that, any deletion in segment 1, 2 and 3 
was sufficient to convert these RNAs into DI-RNAs and inhibitory activity was independent of 
the target segment, in keeping with findings reported by Meng and colleagues (Meng et al. 
2017). These findings support the replication interference concept and suggest that any 
deletion of sequences located between the conserved regions at the ’ and ’ ends of 
genomic segments, which are required for translation and transcription, should generate DI-
RNAs. Indeed, the ’ and ’ ends of DI-RNAs were reported exhibit similar sequences that 
are conserved in all influenza virus strains (Saira et al. 2013; Jennings et al. 1983). 
It has been reported that DI-RNAs are frequently generated from genomic IAV segments 1-3, 





and Nayak 1979). The reason for the preferential accumulation of deletions in these 
segments is their length, which makes them prone to internal deletions during genome 
replication (Nayak et al. 1985). Although the deletions present in these DI-RNAs are central 
to antiviral activity, the expression of truncated viral proteins from these DI-RNAs could 
contribute to antiviral activity (Boergeling et al. 2015). However, the truncated PB2 protein 
encoded by DI-244 did not contribute to the antiviral activity. Thus, overexpression of the 
truncated PB2 protein did not result in inhibition of IAV genome replication and mutating 
ATG start codons in DI-244 did not affect the inhibitory activity of DI-244 (Meng et al. 2017).  
To investigate a potential contribution of IFN to DIP antiviral activity, it was necessary to set 
up conditions to ensure activation of hemagglutinin (HA) protein without trypsin as it 
inactivates IFN (Seitz et al. 2012). For this, IAV strain A/WSN/33 (WSN) was used, which does 
not depend on HA activation by trypsin for acquisition of infectivity. Addition of WSN-
derived DIPs to target cells at 24 h before addition of IAV (subsequently termed 24 h setting) 
boosted antiviral activity as compared to addition of DIPs and IAV at the same time 
(subsequently termed 0 h setting). This suggested that activation of the IFN system could 
play a major role in DIP antiviral activity. Unexpectedly, the presence or absence of trypsin 
did not modulate antiviral activity, indicating that the enhanced antiviral activity observed in 
the 24 h setting did not require production of IFN-α. Finally, it is worth mentioning that DI-
RNA segment length did not impact antiviral activity in the 24 h setting, suggesting that 
different mechanisms account for DIP antiviral activity in the 0 and 24 h setting  
In order to determine the contribution of IFN to DIP antiviral activity, IFN-competent human 
A549 wt cells and A549 STAT1-/- cells were used. Type I IFN triggers the expression of about 
400 genes, many of which encode proteins with antiviral activity, including Mx1 (Schoggins 
et al. 2011). To confirm the STAT1 knock-out on a functional level, Mx1-induction by IAV and 
DI-244 particles were analysed. Both particles induced Mx1 expression in A549 wt cells but 
not in A549 STAT1-/- cells. Holzinger and colleagues reported similar findings for IAV but in 
their study Mx1 induction by IAV was less efficient as compared to IFN-α (Holzinger et al. 
2007). In contrast, Marcos-Villar and colleagues and the present study observed the 
opposite trend (Marcos-Villar et al. 2018). Substantial differences in the IFN-α preparations, 





differences in the findings. Nevertheless, the results are in concordance with the expected 
defect in IFN signalling in A549 STAT1-/- cells. 
It was then investigated whether DI-244 antiviral activity was STAT1-dependent, using the 24 
h setting. When A549 STAT1-/- cells were exposed to the highest amount of DIPs analysed, 
potent anti-IAV activity was observed. Nonetheless, when 10-fold diluted DI-244 was 
analysed, markedly reduced anti-IAV activity was observed in STAT1-/- cells as compared to 
wt cells. Thus, the anti-IAV activity of DI-244 was partially dependent on an intact STAT1 
gene. In contrast, the ability of DI-244 to inhibit VSV infection was fully STAT1-dependent, 
independent of the DIP dilution analysed. Several observations could explain why IAV 
inhibition by DI-244 was not STAT1-dependent when the highest amount of DIPs was 
investigated. First, it is possible that IAV inhibition under those conditions was independent 
of the IFN system. Apparently, cells exposed to a high amount of DI-RNAs can induce a pro-
survival program, dependent on RLR signalling pathway, which may protect cells from dying 
during infection (Vignuzzi and López 2019). Second, it is possible that certain ISGs with anti-
IAV activity are upregulated by DI-244 in a STAT1-independent fashion. This agrees with a 
previously study which reported that STAT1 gene is dispensable for IRF3 dependent 
stimulation of ISG expression (Wang et al. 2017).  Third, another possibility is that IRF9 and 
STAT2 could induce an antiviral effect independent of STAT1 by fusion of IRF9 with 
transcriptional activation domain of STAT2 containing binding sites for transcription 
coregulators (Kraus et al. 2003). Finally, unphosphorylated-ISGF3  alone can induce an 
antiviral effect (Cheon et al. 2013).  Collectively, it can be stated, DI-244 induces anti-IAV 
activity partially independent of STAT1.  
The finding that DI-244 anti-IAV activity was partially STAT1-dependent whereas anti-VSV-
activity was fully dependent open two possibilities. Whether DI-244 induces an antiviral 
state through IFN expression, which signals in a STAT1-dependent manner, or directly 
through ISG expression, which is the consequence of IFN induced, STAT1-dependent 
signalling. To determine whether DI-244 induced expression of type I, II, III IFNs in A549 cells 
a bioassay was performed. Briefly, supernatants harvested from IAV, VSV or DI-244 exposed 
cells were heated and acid treated (followed by neutralization) to inactivate residual virus. 
As it has been reported that both type I (IFN-β) and type III (IFN-λ) are acid-stable, but only 





However, it needs to be stated that another study reported that IFN-λ is acid-sensitive (Reid 
et al. 2016). Afterwards, supernatants or IFN-α (used for standardization) was inoculated 
onto fresh A549 cells in order to trigger an antiviral state, followed by VSV infection and 
quantification of infection. The quantification showed that supernatant of IAV-infected cells 
induced an antiviral state in target cells that inhibited VSV infection in a STAT1-dependent 
manner, as expected. Similar results were obtained for cells exposed to supernatants from 
VSV infected cells, but inhibition was independent of STAT1. Surprisingly, supernatants from 
DI-244 exposed cells did not induce any antiviral state.  
To confirm that DIPs do not induce IFN and to determine whether DIPs induce expression of 
ISGs, RNAseq analysis was conducted. This analysis showed that neither IAV nor DI-244 
induced expression of IFN receptors while IAV but not DI-244 induced expression of IFN. 
Regardless of the discrepancy in upregulation of IFNs by IAV and DI-244, both induced 
expression of a broad panel of ISGs, although IAV was more efficient than DI-244 in ISG 
induction. These results were confirmed with qRT-PCR and concluded that DI-244 induces 
ISGs in a STAT1-dependent but IFN-independent manner. Notably, a recent study confirmed 
that DIPs can efficiently induce ISGs in the absence of robust type I and III IFN expression 
(Wang et al. 2020). The mechanism behind this induction is unknown. In the absence of IFN, 
expression of a subset of ISGs can be induced by IRF7 (Schmid et al. 2010). For instance, 
ISG56 is upregulated by IRF3 in an IFN-independent manner through ISREs present in the 
ISG56 promoter (Grandvaux et al. 2002). However, in the present screen, no STAT1-
independent DIP induced upregulation of ISGs with anti-IAV activity was observed. 
In conclusion, this study provides evidence that induction of IFN system is a major 
contributor of DIP antiviral activity. Having said this, the induction of IFN system does not 
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